

Supplemental material for:

**Cu(II)-PHOX Catalyzed Enantioselective Malonate
Addition onto 3-Hydroxy 2-Oxindoles: Application in the
Synthesis of Dimeric Pyrroloindoline Alkaloids***

K. Naresh Babu,^a Lakshmana K. Kinthada,^a Partha Pratim Das,^b and Alakesh Bisai*^a

^a*Department of Chemistry, Indian Institute of Science Education and Research Bhopal, Bhauri,
Bhopal, MP - 462 066, India.* ^b*Department of Chemistry, Indian Institute of Technology Kanpur,
UP – 208 016, India*


Table of Contents

Materials and methods	S2
Synthesis of compound 14	S3
Synthesis of compounds 15a-b	S4 – S5
Synthesis and characterization of 13b	S5
General synthetic procedure of compounds (±)- 5a-e	S6 – S8
General synthetic procedure of compounds (±)- 5f-g	S8 – S9
General synthetic procedure of compounds (±)- 5h-j	S9 – S10
Synthesis and characterization of 5k	S11 – S12
Synthesis and characterization of 5l	S12 – S13
General synthetic procedure of compounds (±)- 4a-t	S13
Exhaustive optimization of enantioselective malonate addition	S13 – S15
General synthetic procedure of compounds (<i>R</i>)- 4a-s , (+)- 4t	S15 – S29
Synthesis and characterization of (<i>R</i>)- 8	S29 – S30
Synthesis and characterization of (<i>R</i>)- 9	S30 – S31
Synthesis and characterization of 10	S31 – S32
Synthesis and characterization of 11	S32 – S33
Synthetic procedure and characterization of compound (<i>S,S</i>)- 12	S33 – S34
Synthesis of compound (±)- 17	S34 – S36
Synthesis of compound (±)- 19	S36 – S37
References and notes	S37
Spectral graphics	S38 – S143
Crude NMR of compound 10 , (±)- 17 and (±)- 18	S144 – S146
HPLC data	S147 – S198
EPR study of Cu-PHOX complex	S199 – S201
¹ H and ³¹ P NMR study	S201 – S206
Cyclic voltagram study	S206 – S207
X-ray structure of Cu-PHOX complex	S207 – S211


Materials and Methods

Unless otherwise stated, reactions were performed in oven-dried glassware fitted with rubber septa under an inert atmosphere and were stirred with Teflon-coated magnetic stirring bars. Liquid reagents and solvents were transferred *via* syringe using standard Schlenk techniques. Tetrahydrofuran (THF) and diethyl ether (Et₂O) were distilled over sodium/benzophenone ketyl. Dichloromethane (CH₂Cl₂), toluene, and benzene were distilled over calcium hydride. All other solvents and reagents were used as received unless otherwise noted. Reaction temperatures above 23 °C refer to oil bath temperature. Thin layer chromatography was performed using silica gel 60 F-254 precoated plates (0.25 mm) and visualized by UV irradiation, anisaldehyde stain and other stains. Silica gel of particle size 100-200 mesh was used for flash chromatography. Melting points were recorded on a digital melting point apparatus and are uncorrected. ¹H and ¹³C NMR spectra were recorded 400, 500 MHz spectrometers with ¹³C operating frequencies of 100, 125 MHz respectively. Chemical shifts (δ) are reported in ppm relative to the residual solvent (CDCl₃) signal (δ = 7.26 for ¹H NMR and δ = 77.0 for ¹³C NMR). Data for ¹H NMR spectra are reported as follows: chemical shift (multiplicity, coupling constants, and number of hydrogen). Abbreviations are as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad). IR spectra were recorded on a FT-IR system (Spectrum BX) and are reported in frequency of absorption (cm⁻¹). Only selected IR absorbencies are reported. High-Resolution Mass Spectrometry (HRMS) and Low-Resolution Mass Spectrometry (LRMS) data were recorded on MicrOTOF-Q-II mass spectrometer using methanol as solvent. Optical rotations were measured on an Autopol I automatic polarimeter. Enantiomeric excess was determined by chiral HPLC analysis performed on HPLC system with Daicel Chiralpak AD-H, Chiralpak OD-3, Chiralpak OZ-3 and Chiralpak IB, Chiralpak ID-3, columns.


Compounds **13b-c**, **14** and **15a-b** were synthesized as per literature known protocol.¹




Synthetic preparation of compound 14: To the solution of 5-bromoisatin (750 mg, 3.3 mmol, 1.0 equiv) in toluene (30 mL) under nitrogen atmosphere at 25 °C was added ethylene glycol (3.6 mL, 62.4 mmol, 19.0 equiv) and *p*-toluenesulphonic acid (28.5 mg, 0.2 mmol, 0.05 equiv). Then the reaction mixture was placed over a pre heated oil bath maintaining temperature 110 °C and stirring was continued for 4 h. Upon completion of starting material (judged by TLC analysis under UV light and I₂ stain), reaction mixture was cooled down to room temperature to dryness and residue was diluted with dichloromethane (10 mL) and washed with saturated sodium bicarbonate solution (5 mL). Then the organic compound was extracted with dichloromethane (10 mL X 3). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using 30-40% (EtOAc/Hexane) as eluent to afford the desired product.




3-(5-Bromo-1H-indol-3-yl)-3-hydroxyindolin-2-one:¹ Compound **14** was obtained as colorless solid. (3.3 mmol scale of reaction, 812 mg of product, 91% yield); *R_f* = 0.60 (50% EtOAc in hexane); ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.47 (m, 1H), 7.43 - 7.41 (m, 1H), 6.72 (d, *J* = 8.3 Hz, 1H), 4.56 - 4.52 (m, 2H), 4.33 - 4.30 (m, 2H).



General procedure for the synthesis of compound 15a-b:¹ To a solution of **14** (1.0 equiv) in ethylene glycol dimethyl ether (4 mL) under nitrogen atmosphere at 25 °C was added dichloro bis(triphenylphosphine)palladium(II) (0.03 equiv.). After 15 minutes stirring, phenylboronic acid (1.5 equiv), sodium bicarbonate (3.0 equiv), and water (4 mL) was added simultaneously. Then the reaction mixture was placed over a pre heated oil bath maintaining temperature 120 °C and stirring was continued for 2 h. Upon completion of starting material (judged by TLC analysis under UV light and I₂ stain), the reaction mixture was cooled down to 25 °C and. evaporated to dryness and residue was diluted with dichloromethane (20 mL) and washed with 10% sodium hydroxide solution (15 mL). The aqueous layer was extracted with dichloromethane (10 mL X 3). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using 30-40% (EtOAc/Hexane) as eluent to afford the desired product.




5'-Phenylspiro[[1,3]dioxolane-2,3'-indolin]-2'-one:¹ Compound **15a** was obtained as colorless solid (3.4 mmol scale of reaction, 720 mg of product, 80% yield); R_f = 0.55 (50% EtOAc in hexane); ¹H NMR (500 MHz, 0.5 mL CDCl₃) δ 8.41 (brs, 1H), 7.59 - 7.58 (m, 1H), 7.53 - 7.50 (m, 3H), 7.42 - 7.39 (m, 2H), 7.33 - 7.30 (m, 1H), 6.88 (d, J = 8.1 Hz, 1H), 4.60 - 4.58 (m, 2H), 4.36 - 4.34 (m, 2H).




5'-(3-Methoxyphenyl)spiro[[1,3]dioxolane-2,3'-indolin]-2'-one:¹ Compound **15b** was obtained as colorless solid (3.3 mmol scale of reaction, 590 mg of product, 60% yield); R_f = 0.56 (50% EtOAc in hexane); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.67 (brs, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.50 (dd, J = 8.1, 1.9 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.11 -


7.05 (m, 2H), 6.88 - 6.84 (m, 2H), 4.60 - 4.57 (m, 2H), 4.36 - 4.33 (m, 2H), 3.84 (s, 3H); ^{13}C NMR (120 MHz, CDCl_3) δ 175.8, 159.9, 141.9, 141.3, 136.7, 136.5, 129.8, 124.9, 124.1, 119.4, 112.6, 112.5, 111.0, 102.5, 65.9, 55.3; **MP** 150 - 152 °C.




General procedure for the synthesis of compound 13b-c:¹ To the compound of **15** (1.0 equiv) in methanol (9 mL) at 25 °C was added conc. HCl (4 mL). Then the reaction mixture was placed over a pre heated oil bath maintaining temperature 70 °C for 5 h. Upon completion of starting material (judged by TLC analysis under UV light and cerium ammonium molybdate stain), the reaction mixture was evaporated to dryness. The residue was diluted with dichloromethane and washed with saturated sodium bicarbonate solution. Then the organic compound was extracted with dichloromethane (10 mL X 3). Then the combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using 35-45% (EtOAc/Hexane) as eluent to afford the desired product.




5-Phenylindoline-2,3-dione: Compound **13b** was obtained as colourless solid. (2.2 mmol scale of reaction; 400 mg of product; 80% yield; R_f = 0.50 (50% EtOAc in hexane); ^1H NMR (400 MHz, DMSO) δ 10.38 (s, 1H), 7.77 - 7.75 (m, 1H), 7.7 (dd, J = 8.1, 2.0 Hz, 1H), 7.51 - 7.48 (m, 2H), 7.45 - 7.36 (m, 2H), 7.37 - 7.32 (m, 1H), 2.27 (DMSO).



General procedure for the synthesis of 3-Hydroxy-3-indolyl-2-oxindole (\pm)-5a-e: In a round-bottom flask was charged with isatin (1.0 equiv) in MeOH (60 mL) under nitrogen atmosphere at 25 °C indole (1.2 equiv) and KOH (0.2 equiv) were added successively. Then the reaction mixture was then allowed to stir for 4 - 6 h. Upon completion of starting material (judged by TLC analysis under UV light and I₂ stain), the reaction mixture was quenched with water (60 mL) and organic compound was extracted with ethyl acetate (2 X 80 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using hexane-EtOAc as eluent to afford the desired product.




3-Hydroxy-3-(1H-indol-3-yl)indolin-2-one:² Compound (\pm)-5a was obtained as a colorless solid (13.6 mmol scale of reaction, 3.2 g of product, 88% yield); R_f = 0.30 (50% EtOAc in hexane); ¹H NMR (400 MHz, DMSO) δ 10.94 (s, 1H), 10.32 (s, 1H), 7.31 - 7.28 (m, 2H), 7.24 - 7.19 (m, 2H), 7.06 (s, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.94 - 6.88 (m, 2H), 6.83 (t, J = 7.4 Hz, 1H), 6.37 (s, 1H), 3.68 (Water); IR (film) ν_{\max} 3428, 2839, 2115, 1650, 1470, 1337, 1226, 1185, 1105, 940, 751 cm⁻¹; MP 350-352 °C.




3-(5-Bromo-1H-indol-3-yl)-3-hydroxyindolin-2-one: Compound (\pm)-5b was obtained as a colorless solid (6.8 mmol scale of reaction, 1.95 g of product, 84% yield); R_f = 0.30 (50% EtOAc in hexane); ¹H NMR (500 MHz, DMSO) δ 11.22 (s, 1H), 10.41 (s, 1H), 7.75 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.32 - 7.28 (m, 2H), 7.21 (d, J = 8.2 Hz, 1H), 7.05 -


7.01 (m, 2H), 6.97 (d, $J = 7.4$ Hz, 1H), 6.55 (s, 1H); ^{13}C NMR (125 MHz, DMSO) δ 178.8, 142.1, 136.0, 133.3, 129.8, 127.4, 125.6, 125.3, 124.2, 123.6, 122.4, 115.7, 114.1, 111.8, 110.3, 75.2; **IR** (film) 3420, 1792, 1644, 1469, 1245, 1170, 815, 697 cm^{-1} ; **MP** 190 - 192 $^{\circ}\text{C}$.




3-Hydroxy-3-(5-methoxy-1H-indol-3-yl)indolin-2-one: Compound (±)-**5c** was obtained as a colorless solid. (6.5 mmol scale of reaction, 1.7 g of product, 89% yield); $R_f = 3.1$ (50% EtOAc in hexane); ^1H NMR (400 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.64 (s, 1H), 9.54 (s, 1H), 7.17 (d, $J = 6.9$ Hz, 1H), 7.01 - 6.96 (m, 2H), 6.86 - 6.82 (m, 2H), 6.76 (t, $J = 7.2$ Hz, 1H), 6.69 (d, $J = 7.4$ Hz, 1H), 6.51 (d, $J = 8.6$ Hz, 1H), 5.49 (s, 1H), 3.49 (s, 3H), 2.69 (s, 1H); ^{13}C NMR (100 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 179.3, 153.4, 141.4, 132.8, 132.2, 129.1, 125.4, 124.9, 124.3, 122.1, 114.8, 112.0, 111.6, 110.0, 102.5, 75.6, 55.5; **IR** (film) ν_{max} 3416, 2861, 2832, 2106, 1792, 1704, 1622, 1469, 1071, 904, 751 cm^{-1} ; **MP** 194 - 196 $^{\circ}\text{C}$.




3-(6-bromo-1H-indol-3-yl)-3-hydroxyindolin-2-one: Compound (±)-**5d** was obtained as a colorless solid. (6.8 mmol scale of reaction, 2.05 g of product, 88% yield); $R_f = 2.5$ (50% EtOAc in hexane); ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.14 (s, 1H), 10.38 (s, 1H), 7.57 (s, 1H), 7.44 (d, $J = 8.6$ Hz, 1H), 7.29 - 7.25 (m, 2H), 7.08 - 7.07 (m, 2H), 7.01 - 6.98 (m, 1H), 6.94 (d, $J = 7.2$ Hz, 1H), 6.49 (s, 1H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 178.8, 142.1, 138.2, 133.5, 129.7, 125.2, 125.1, 124.6, 122.8, 122.3, 122.0, 116.3, 114.6, 114.5, 110.3, 75.2, 75.2; **IR** (film) ν_{max} 3500, 2950, 2800, 2520, 1802, 1706, 1602, 1499, 1001, 984, 721 cm^{-1} ; **MP** >260 $^{\circ}\text{C}$.




3-hydroxy-3-(7-iodo-1H-indol-3-yl)indolin-2-one: Compound (±)-**5e** was obtained as a colorless solid. (6.5 mmol scale of reaction, 2.02 g of product, 80% yield); $R_f = 2.9$ (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, DMSO- D_6) δ 10.9 (s, 1H), 10.40 (s, 1H), 7.48 – 7.42 (m, 2H), 7.29 – 7.24 (m, 2H), 7.07 (s, 1H), 7.99 – 6.93 (m, 2H), 6.74 (s, 1H), 6.47 (s, 1H); $^{13}\text{C NMR}$ (100 MHz, DMSO- D_6) δ 178.6, 142.1, 138.9, 133.5, 130.6, 129.7, 125.9, 125.2, 124.8, 122.3, 121.0, 117.4, 110.2, 77.4, 75.5; **IR** (film) ν_{max} 3560, 2960, 2852, 2116, 1709, 1662, 1409, 1001, 924, 701 cm^{-1} ; **MP** >260 °C.




General procedure for the synthesis of 3-Hydroxy-3-indolyl-2-oxindole (±)-5f-g: In a round bottom flask was charged with isatin (1.0 equiv) in MeOH (60 mL) under nitrogen atmosphere at 25 °C indole (1.2 equiv) and KOH (0.2 equiv) were added successively. Then the reaction mixture was then allowed to stir for 5-6 h. Upon completion of starting material (judged by TLC analysis under UV light and I_2 stain), the reaction mixture was quenched with water (60 mL) and organic compound was extracted with ethyl acetate (2 X 80 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using hexane-EtOAc as eluent to afford the desired product.




5-Bromo-3-hydroxy-3-(1*H*-indol-3-yl)indolin-2-one: Compound (±)-**5f** was obtained as a colorless solid. (3.3 mmol scale of reaction, 1.0 g of product, 84% yield); $R_f = 3.2$ (50% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, DMSO) δ 11.06 (s, 1H), 10.58 (s, 1H), 7.46 (d, $J = 7.3$ Hz, 1H), 7.38 (m, 3H), 7.19 (s, 1H), 7.08 (d, $J = 12.6$ Hz, 1H), 6.95 - 6.93 (m, 2H), 6.66 (s, 1H), (Water); $^{13}\text{C NMR}$ (125 MHz, DMSO) δ 178.5, 141.4, 137.3, 136.3, 132.3, 127.9, 125.1, 124.1, 121.8, 120.4, 119.3, 115.1, 114.0, 112.4, 112.2, 75.3; **IR** (film) ν_{max} 3416, 1792, 1644, 1492, 1335, 1247, 1177, 1121, 815, 715 cm^{-1} ; **MP** 310 - 312 $^{\circ}\text{C}$.




3-Hydroxy-3-(1*H*-indol-3-yl)-5,7-dimethylindolin-2-one: Compound (±)-**5g** was obtained as a colorless solid (3.9 mmol scale of reaction, 1.0 g of product, 90% yield); $R_f = 0.55$ (50% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO-}D_6$) δ 10.93 (s, 1H), 10.53 (s, 1H), 7.32 (dd, $J = 47.6, 8.2$ Hz, 2H), 7.02 (t, $J = 7.6$ Hz, 1H), 6.86 - 6.79 (m, 3H), 3.38 (s, 3H), 2.23 (d, $J = 67.2$ Hz, 3H); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}D_6$) δ 179.7, 137.9, 137.4, 134.7, 130.5, 129.9, 126.2, 124.8, 123.3, 121.4, 121.3, 118.9, 118.6, 115.1, 112.0, 55.4, 21.2, 1; **IR** (film) ν_{max} 3387, 3304, 2924, 2852, 1735, 1701, 1624, 1544, 1465, 1286, 1099, 740, 617 cm^{-1} ; **MP** 210 - 212 $^{\circ}\text{C}$.



General procedure for the synthesis of 3-Hydroxy-3-indolyl-2-oxindoles (±)-5h-j** is like synthesis of (±)-**5f-g**.**




3-Hydroxy-3-(1*H*-indol-3-yl)-5-phenylindolin-2-one: Compound (±)-**5h** was obtained as a colorless solid (3.5 mmol scale of reaction, 930 mg of product, 78% yield); R_f = 3.2 (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, DMSO- D_6) δ 10.96 (s, 1H), 10.42 (s, 1H), 7.55 - 7.47 (m, 3H), 7.41 - 7.22 (m, 5H), 7.01 (s, 1H), 7.01 - 6.82 (m, 3H), 6.41 (s, 1H), 3.32 (Water); $^{13}\text{C NMR}$ (125 MHz, DMSO- D_6) δ 178.9, 141.7, 140.6, 137.2, 134.6, 134.3, 129.4 (2C), 127.9, 127.2, 126.5 (2C), 125.3, 124.1, 123.4, 121.5, 120.7, 118.9, 115.7, 111.9, 110.5, 75.5; **IR** (film) ν_{max} 3415, 3387, 2922, 2850, 2357, 1714, 1624, 1389, 1172, 744, 694 cm^{-1} ; **MP** > 300 °C.




3-Hydroxy-3-(1*H*-indol-3-yl)-5-(3-methoxyphenyl)indolin-2-one: Compound (±)-**5i** was obtained as an orange solid (2.0 mmol scale of reaction, 555 mg of product, 75% yield); R_f = 3.3 (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, DMSO- D_6) δ 10.96 (s, 1H), 10.42 (s, 1H), 7.55 (d, J = 8.1 MHz, 1H), 7.49 (s, 1H), 7.42 (d, J = 8.1 MHz, 1H), 7.32 - 7.25 (m, 2H), 7.09 - 7.06 (m, 2H), 7.02 - 6.95 (m, 3H), 6.87 - 6.81 (m, 2H), 6.41 (s, 1H), 3.75 (s, 3H), 3.33 (Water); $^{13}\text{C NMR}$ (125 MHz, DMSO- D_6) δ 183.7, 164.9, 146.8, 146.6, 142.0, 139.3, 138.9, 135.1, 132.8, 130.1, 128.4, 128.2, 126.3, 125.5, 123.7, 123.6, 120.5, 117.6, 116.7, 116.6, 115.2, 80.2, 60.3; **IR** (film) ν_{max} 3388, 2926, 2355, 1712, 1641, 1624, 1579, 1477, 1392, 1165, 1082, 821, 740 cm^{-1} ; **MP** > 300 °C.


Compound (±)-**5j** was prepared as per literature report.³



Compound (±)-**9a**⁴ and compounds (±)-**9b-d**⁵ were synthesized as per literature reports.




Synthetic procedure for the compound (±)-5k: In an oven-dried round bottom flask was charged with oxindole (±)-**5a** (1 g; 3.8 mmol; 1.0 equiv) in dichloromethane (15 mL) under nitrogen atmosphere at 25 °C Lewis acid (0.38 mmol, 10 mol %) and MeOH (765 μ L; 18.9 mmol, 5.0 equiv) was added. Then the reaction mixture was allowed to stir for 12 h. Upon completion of starting material (judged by TLC analysis under UV light and I_2 stain), the reaction mixture was quenched with water (20 mL) and organic compound was extracted with ethyl acetate (2 X 30 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using 25-40% (EtOAc/Hexane) as eluent to afford the desired product.




3-(1*H*-Indol-3-yl)-3-methoxyindolin-2-one: Compound (±)-**5k** was obtained as an orange solid (3.0 mmol scale of reaction, 760 mg of product, 92% yield); R_f = 3.3 (50% EtOAc in hexane); ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.08 (s, 1H), 10.58 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.34 (dd, J = 13.9, 7.6 Hz, 3H), 7.06 (q, J = 8.1 Hz, 2H), 6.97 - 6.92 (m, 3H), 3.43 (Water), 3.15 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 176.4, 142.8, 137.2, 130.3, 128.8, 125.7, 125.5, 124.8, 122.4, 121.8, 121.4, 119.2, 113.2, 112.0, 110.5,

81.7, 52.3; **IR** (film) ν_{max} 3338, 2956, 2354, 1710, 1621, 1616, 1569, 1470, 1292, 1105, 1012, 921, 750 cm^{-1} .




Synthetic procedure for the compound (±)-5I: In an oven-dried round bottom flask was charged with isatin (1g; 6.8 mmol; 1.0 equiv) in methyl *tert*-butyl ether (15 mL) under nitrogen atmosphere at 25 °C. To this solution, sesamol (8.2 mmol, 1.2 equiv) and Et_3N (1.3 mmol, 20 mol%) was added sequentially and the reaction mixture was allowed to stir for 15 h. Upon completion of starting material (judged by TLC analysis), the reaction mixture was quenched with water (20 mL) and organic compound was extracted with ethyl acetate (2 X 30 mL). Then the combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. This crude product was used for next step without purification.

To the crude product of 3-hydroxy 2-oxindoles (~6.3 mmol; 1.0 equiv) in dichloromethane (30 mL) under nitrogen atmosphere at 25 °C Lewis acid (~0.63 mmol, 10 mol %) and MeOH (~31.5 mmol, 5.0 equiv) was added. Then the reaction mixture was allowed to stir for 12 h. Upon completion of starting material (judged by TLC analysis under UV light and I_2 stain), the reaction mixture was quenched with water (30 mL) and organic compound was extracted with ethyl acetate (2 X 40 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography using 30-40% ($\text{EtOAc}/\text{Hexane}$) as eluent to afford the desired product.





3-(6-Hydroxybenzo[*d*][1,3]dioxol-5-yl)-3-methoxyindolin-2-one: Compound (±)-**5l** was obtained as orange solid (6.8 mmol scale of reaction, 1.7 g of product, 86% yield over two steps); $R_f = 3.3$ (50% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ 10.50 (s, 1H), 9.19 (s, 1H), 7.21 (ddd, $J = 7.8, 5.9, 3.0$ Hz, 1H), 7.16 (s, 1H), 6.91 - 6.89 (m, 2H), 6.84 (d, $J = 7.7$ Hz, 1H), 6.27 (s, 1H), 5.93 (d, $J = 8.6$ Hz, 2H), 3.46 (Water), 3.04 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$) δ 176.3, 148.9, 147.2, 144.2, 140.0, 129.8, 128.7, 124.8, 122.1, 118.8, 109.7, 106.9, 101.2, 98.0, 81.0, 51.4; **IR** (film) ν_{max} 3382, 2916, 2255, 1722, 1631, 1614, 1568, 1452, 1390, 1105, 1002, 911, 720 cm^{-1} .



General procedure for the synthesis of (±)-4a-t: 3-Hydroxy 2-oxindoles (0.38 mmol; 1.0 equiv) was taken in dry dichloromethane (2 mL) under nitrogen atmosphere and 10 mol % Cu(OTf)_2 was added to this at room temperature under argon atmosphere. After 5 minutes stirring at room temperature, malonate (3 equiv) was added drop-wise over a period of 5 minutes. Then the reaction mixture was allowed to stir for 9 h. Upon completion of starting material (judged by TLC analysis under UV light and I_2 stain), the crude mixture was concentrated under reduced pressure and product was purified by column chromatography by using 25-40% (EtOAc/Hexane) as eluent to afford the desired products.

Table. Optimization of enantioselective malonate addition of (±)-**5a** with diethylmalonate.^{a,b}




entry	catalyst	ligand	solvent	temp.	time	% yield	% ee
1	Cu(OTf) ₂	12 mol% L1	CH ₂ Cl ₂	25 °C	12 h	79%	52%
2	Cu(OTf) ₂	12 mol% L2	CH ₂ Cl ₂	25 °C	13 h	80%	38%
3	Cu(OTf) ₂	12 mol% L3	CH ₂ Cl ₂	25 °C	12 h	81%	51%
4	Cu(OTf) ₂	12 mol% L4	CH ₂ Cl ₂	25 °C	13 h	84%	72%
5	Cu(OTf) ₂	12 mol% L4	CH ₂ Cl ₂	0 °C	16 h	83%	82%
6	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	0 °C	15 h	84%	92%
7	Cu(OTf) ₂	10 mol% L4	CH ₂ Cl ₂	0 °C	17 h	75%	80%
8 ^c	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	0 °C	16 h	79%	86%
9	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	-5 °C	16 h	75%	88%
10	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	-5 °C	28 h	83%	94%
11	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	-10 °C	45 h	69%	88%
12	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	-15 °C	21 h	70%	75%
13	Cu(OTf) ₂	20 mol% L4	CH ₂ Cl ₂	0 - 25 °C	12 h	85%	82%
14	Cu(OTf) ₂	20 mol% L4	PhMe	0 °C	12 h	75%	71%
15	Cu(OTf) ₂	20 mol% L4	THF	0 °C	6 h	83%	14%
16	Cu(OTf) ₂	20 mol% L4	CHCl ₃	0 °C	9 h	55%	61%
17	Cu(OTf) ₂	20 mol% L4	(CH ₂ Cl) ₂	0 °C	20 h	55%	22%
18	Cu(OTf) ₂	20 mol% L4	DCB ^c	0 °C	15 h	85%	59%
19	Cu(OTf) ₂	20 mol% L5	CH ₂ Cl ₂	0 °C	19 h	78%	24%

20	Cu(OTf) ₂	20 mol% L6	CH ₂ Cl ₂	0 °C	19 h	72%	39%
21	Cu(OTf) ₂	20 mol% L7	CH ₂ Cl ₂	0 °C	17 h	80%	40%
22	In(OTf) ₃	20 mol% L4	CH ₂ Cl ₂	0 °C	15 h	20%	00%
23	Cu(OTf).P hMe	12 mol% L4	CH ₂ Cl ₂	0 °C	17 h	82%	77%
24	Cu(OTf).P hMe	20 mol%	CH ₂ Cl ₂	0 °C	16 h	86%	83%

^aAll the reactions were carried out on a 0.08 mmol of **5a**, 0.23 mmol of dialkylmalonate in 3 mL of dichloromethane at 0 °C. ^bIsolated yields after column chromatography. ^cReactions were carried out on a 0.08 mmol of **5a**, 0.16 mmol of dialkylmalonate in 3 mL of dichloromethane at 0 °C.


General procedure for the synthesis of enantioselective compounds: (*R*)-4a-s**, (+)-**4t**:**

An oven dried sample vial was charged with Lewis acid (0.1 equiv) and ligand (0.2 equiv) in dichloromethane (4 mL) at 25 °C under nitrogen atmosphere. The reaction mixture was stirred for 30 minutes to make the complex. After that the reaction vessel was cooled to 0 °C and malonate (3.0 equiv) was added to the mixture and stirring was continued for 15 minutes maintaining temperature 0 °C. Then, a solution of 3-hydroxy 2-oxindole in dichloromethane (0.5 mL) was added slowly to the reaction mixture. Then the reaction mixture was allowed to stir for respective times at 0 °C for condition A and -5 °C for condition B. After complete consumption of starting material (as judged by running TLC), the crude mixture was concentrated under reduced pressure and purified by column chromatography by using 30-40% EtOAc-hexane mixture as eluent to afford the desired compound.




Diethyl (*R*)-2-(3-(1*H*-indol-3-yl)-2-oxindolin-3-yl)malonate: Compound (*R*)-**4a** was obtained as yellow solid (0.08 mmol scale of reaction, 26 mg of product, 80% yield); R_f = 0.50 (50% EtOAc in hexane); ¹H NMR (400 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-*D*₆) δ 9.63 (brs, 1H), 9.49 (brs, 1H), 7.80 (d, *J* = 7.2 Hz, 1H), 7.63 (d, *J* = 7.7 Hz, 1H), 7.10 (t, *J*


= 8.3 Hz, 2H), 6.91 - 6.80 (m, 3H), 6.76 (d, $J = 7.7$ Hz, 1H), 6.51 - 6.50 (m, 1H), 4.99 (s, 1H), 3.77 - 3.66 (m, 4H), 0.76 (t, $J = 14.2$ Hz, 3H), 0.62 (t, $J = 14.2$ Hz, 3H); ^{13}C NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 178.4, 167.3, 166.9, 142.5, 136.9, 129.8, 128.3, 126.9, 124.9, 124.2, 121.7, 121.4, 121.3, 118.8, 111.9, 111.2, 109.5, 61.1, 60.6, 56.4, 53.4, 13.2, 13.1; **IR** (film) ν_{max} 3375, 2989, 2359, 1724, 1615, 1265, 1034, 747, 700 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_5]^+$ 407.1601; Found 407.1604; **MP** 170 - 172 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined via HPLC analysis using a Chiralpak ID-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 4.88 min, t_R major = 5.92 min. $[\alpha]_D^{23.0} = +128.6$ ($c = 0.18$, CH_2Cl_2 for 94% ee).



Dimethyl (*R*)-2-(3-(1*H*-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4b** was obtained as a colorless solid (0.08 mmol scale of reaction, 24 mg of product, 82% yield); $R_f = 0.48$ (50% EtOAc in hexane); ^1H NMR (500 MHz, 0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.25 (s, 1H), 9.18 (s, 1H), 7.87 (d, $J = 7.6$ Hz, 1H), 7.62 (d, $J = 8.2$ Hz, 1H), 7.20 (t, $J = 7.1$ Hz, 2H), 7.01 (q, $J = 8.0$ Hz, 2H), 6.95 (d, $J = 7.9$ Hz, 1H), 6.86 (d, $J = 7.8$ Hz, 1H), 6.65 (s, 1H), 5.15 (s, 1H), 3.40 (s, 3H), 3.38 (s, 3H); ^{13}C NMR (125 MHz, 0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 178.5, 168.0, 167.4, 142.4, 137.1, 129.8, 128.7, 127.1, 124.9, 124.4, 121.9, 121.7, 121.5, 119.4, 111.9, 111.5, 109.9, 56.5, 53.6, 52.4, 52.2; **IR** (film) ν_{max} 3361, 3059, 2983, 2938, 2308, 1720, 1455, 1316, 1104, 1015, 913, 838, 743 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_5]^+$ 379.1288; Found 379.1309; **MP** 240 - 242 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OZ-3 column; solvent: hexane/2-propanol = 70/30; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 11.71 min, t_R major = 14.29 min. $[\alpha]_D^{22.1} = +250.0$ ($c = 0.22$, CHCl_3 for 89% ee).




Diisopropyl (R)-2-(3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (R)-4c was obtained as a yellow solid (0.08 mmol scale of reaction, 27 mg of product, 79% yield); $R_f = 0.52$ (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.63 (brs, 1H), 8.15 (brs, 1H), 8.05 (d, $J = 6.0$ Hz, 1H), 7.92 (d, $J = 6.3$ Hz, 1H), 7.24 - 7.18 (m, 2H), 7.06 - 7.05 (m, 3H), 6.84 (m, 1H), 6.53 (s, 1H), 5.16 (s, 1H), 4.71 - 4.70 (m, 2H), 1.01 - 0.91 (m, 6H), 0.68 - 0.59 (m, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 179.1, 167.1, 166.6, 141.9, 137.0, 129.9, 128.7, 127.5, 125.1, 124.2, 122.4, 122.3, 122.1, 119.6, 112.8, 111.3, 109.9, 69.5, 68.6, 56.8, 53.7, 21.3, 21.2, 20.6, 20.6; **IR** (film) ν_{max} 3340, 2975, 2340, 2320, 1720, 1620, 1600, 1265, 1005, 1051, 700, 692 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_5]^+$ 435.1914; Found 435.1900; **MP** 110 - 112 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak IB column; solvent: hexane/2-propanol = 40/30; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 5.45 min, t_R major = 6.32 min. $[\alpha]_D^{23.0} = +179.7$ ($c = 0.30$, CHCl_3 for 89% ee).




Ditert-butyl (R)-2-(3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (R)-4d was obtained as a colorless solid. (0.08 mmol scale of reaction, 29 mg of product, 79% yield); $R_f = 0.56$ (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.35 (brs, 1H), 8.11 - 8.02 (m, 3H), 7.28 - 7.25 (m, 2H), 7.12 - 7.04 (m, 3H), 6.88 (d, $J = 7.7$ Hz, 1H), 6.55 (s, 1H), 5.08 (s, 1H), 1.05 (s, 9H), 0.99 (s, 9H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 179.2, 166.8, 166.5, 141.7, 137.1, 130.4, 128.6, 127.7, 125.3, 124.2, 122.90, 122.4, 122.2, 119.6, 113.4, 111.2, 109.6, 82.6, 81.4, 58.1, 53.8, 27.3, 27.1; **IR** (film) ν_{max} 3340, 2975,

2340, 2320, 1720, 1620, 1600, 1265, 1051, 700, 692 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{27}\text{H}_{30}\text{N}_2\text{O}_5 + \text{Na}]^+$ 485.2047; Found 485.2076; **MP** 138 - 140 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_{R} minor = 4.78 min, t_{R} major = 6.86 min. $[\alpha]_{\text{D}}^{23.1} = +105.2$ ($c = 0.18$, CHCl_3 for 77% ee).




(+)-1-Benzyl-3-ethyl-2-(-3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound **(+)-4e** was obtained as a yellow solid (0.08 mmol scale of reaction, 31 mg of product, 83% yield); $R_f = 0.56$ (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 10.97 (brs, 1H for major diastereomer + 1H for minor diastereomer), 10.47 (brs, 1H for minor diastereomer), 10.46 (s, 1H for major diastereomer), 7.76 (d, $J = 7.3$ Hz, 1H for minor diastereomer), 7.71 (d, $J = 7.3$ Hz, 1H for major diastereomer), 7.53 (d, $J = 8.0$ Hz, 1H for major diastereomer), 7.49 (d, $J = 8.1$ Hz, 1H for minor diastereomer), 7.36 - 7.22 (m, 3H for major diastereomer + 3H for minor diastereomer), 7.27 - 7.16 (m, 2H for major diastereomer + 2H for minor diastereomer), 7.04 - 6.95 (m, 3H for major diastereomer + 3H for minor diastereomer), 6.90 - 6.83 (m, 3H for major diastereomer + 3H for minor diastereomer), 6.66 (s, 1H for minor diastereomer), 6.63 (s, 1H for major diastereomer), 5.02 (s, 1H for major diastereomer), 5.01 (s, 1H for minor diastereomer), 4.93 - 4.81 (m, 2H for major diastereomer + 2H for minor diastereomer), 4.35 (Water), 3.81 - 3.80 (m, 2H for major diastereomer + 2H for minor diastereomer), 0.80 (t, $J = 6.9$ Hz, 3H for major diastereomer), 0.65 (t, $J = 6.8$ Hz, 3H for minor diastereomer); $^{13}\text{C NMR}$ (100 MHz, $\text{DMSO}-d_6$) δ 178.1, 177.9, 167.4, 167.3, 166.90, 166.87, 143.5, 143.4, 137.4, 137.3, 135.7, 135.5, 130.2, 130.1, 129.13, 129.11, 128.8, 128.6, 128.5, 128.2, 127.9, 127.7, 127.2, 127.0, 125.3, 125.2, 124.92, 124.91, 121.8, 121.75, 121.72, 121.67, 121.63 (2 C), 119.2, 119.0, 112.5, 112.1, 111.9, 111.8, 110.2, 110.1, 66.9, 66.7, 61.7, 61.1, 56.65, 56.61, 53.5, 53.4, 13.7, 13.6; **IR** (film) ν_{max} 3700, 3464, 2918, 2352, 1725, 1458,


1322, 1241, 1148, 738 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{28}\text{H}_{24}\text{N}_2\text{O}_5 + \text{Na}]^+$ 491.1577; Found 491.1602; **MP** 190 - 192 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak AD-H column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): in case of minor diastereomer (t_{R} minor = 9.40 min, t_{R} major = 17.854 min. 84% ee), in case of major diastereomer (t_{R} minor = 11.88 min, t_{R} major = 22.05 min. 85% ee). $[\alpha]_{\text{D}}^{22.0} = +192.1$ ($c = 0.26$, in CHCl_3).



Dibenzyl (R)-2-(3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4f** was obtained as a yellow solid (0.08 mmol scale of reaction 38 mg of product 90% yield); $R_f = 0.60$ (50% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.99 (d, $J = 7.6$ Hz, 1H), 7.97 (s, 1H), 7.88 (d, $J = 8.2$ Hz, 1H), 7.68 (s, 1H), 7.28 – 7.23 (m, 6H), 7.19 – 7.15 (m, 3H), 7.09 – 7.04 (m, 4H), 6.86 (d, $J = 7.1$ Hz, 2H), 6.73 (d, $J = 7.7$ Hz, 1H), 6.62 (d, $J = 2.7$ Hz, 1H), 5.37 (s, 1H), 4.91 (m, 4H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 178.0, 167.2, 166.7, 141.4, 136.9, 135.0, 134.7, 129.4, 128.7, 128.4, 128.2, 128.2, 128.1, 127.9, 127.9, 127.3, 124.9, 124.3, 122.3, 122.3, 122.0, 120.0, 112.3, 111.4, 109.8, 67.3, 67.0, 56.5, 53.4; **IR** (film) ν_{max} 3390, 2928, 2251, 1729, 1621, 1400, 1360, 1311, 1260, 1100, 1022, 756, 698 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{33}\text{H}_{27}\text{N}_2\text{O}_5]^+$ 531.1914; Found 531.1939; **MP** 180 - 182 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_{R} minor = 4.69 min, t_{R} major = 9.21 min. $[\alpha]_{\text{D}}^{21.0} = +222.6$ ($c = 0.18$, MeOH for >99% ee).




Diethyl (R)-2-(3-(5-methoxy-1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4g** was obtained as a colorless solid (0.08 mmol scale of reaction, 27 mg of product, 73% yield); $R_f = 0.56$ (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, DMSO- D_6) δ 10.82 (s, 1H), 10.46 (s, 1H), 7.76 (d, $J = 7.4$ Hz, 1H), 7.27 (td, $J = 7.7, 0.9$ Hz, 1H), 7.16 (d, $J = 8.8$ Hz, 1H), 7.01 (t, $J = 7.3$ Hz, 1H), 6.90 (d, $J = 7.7$ Hz, 1H), 6.76 (d, $J = 1.8$ Hz, 1H), 6.66 - 6.63 (m, 2H), 4.86 (s, 1H), 3.90 - 3.76 (m, 4H), 3.58 (s, 3H), 3.48 (Water), 0.79 (t, $J = 7.1$ Hz, 3H), 0.75 (t, $J = 7.1$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, DMSO- D_6) δ 178.2, 167.4, 167.0, 153.1, 143.6, 132.4, 130.2, 129.2, 127.3, 125.6, 125.3, 121.7, 112.6, 111.6, 111.4, 110.0, 103.6, 61.6, 61.0, 56.6, 55.6, 53.3, 13.7, 13.7; **IR** (film) ν_{max} 3381, 2982, 1715, 1471, 1371, 1299, 1246, 1189, 1031, 860, 816, 741 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_6 + \text{Na}]^+$ 459.1527; Found 459.1551; **MP** 130 - 132 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak IE-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 8.60 min, t_R major = 10.81 min. $[\alpha]_{\text{D}}^{24.0} = +110.0$ ($c = 0.20$, CHCl_3 for 76% ee).




Diethyl (R)-2-(3-(5-bromo-1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4h** was obtained as a brown solid (0.08 mmol scale of reaction, 30 mg of product, 77% yield); $R_f = 0.56$ (50% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, DMSO- D_6) δ 11.23 (s, 1H), 10.57 (s, 1H), 7.82 - 7.76 (m, 2H), 7.35 - 7.30 (m, 2H), 7.18 (d, $J = 8.7$ Hz, 1H), 7.08 (d, $J = 7.8$ Hz, 1H), 6.94 (t, $J = 6.1$ Hz, 1H), 6.73 (s, 1H), 4.91 (s, 1H), 3.93 - 3.81 (m, 4H), 0.84 (t, $J = 7.1$ Hz, 3H), 0.73 (t, $J = 3.1$ Hz, 3H); $^{13}\text{C NMR}$ (125 MHz, DMSO-


D₆) δ 178.0, 167.2, 166.7, 143.4, 136.1, 129.8, 129.2, 127.0, 126.9, 126.6, 124.1, 124.1, 121.8, 114.2, 111.8, 111.8, 110.1, 61.6, 61.0, 56.7, 53.2, 13.7, 13.6; **IR** (film) ν_{\max} 3260, 3063, 2922, 2359, 1712, 1616, 1469, 1217, 1097, 1018, 746 cm^{-1} ; **HRMS** (ESI) m/z $[M + Na]^+$ Calcd for $[C_{23}H_{21}BrN_2O_5+Na]^+$ 507.0526; Found 507.0534; **MP** 120 - 122 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak IB column; solvent: hexane/2-propanol = 70/30; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 4.72 min, t_R major = 6.65 min. $[\alpha]_D^{24.1} = +198.2$ ($c = 0.19$, CHCl_3 for 88% ee).



Diethyl (R)-2-(5-bromo-3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4i** was obtained as a brown solid (0.08 mmol scale of reaction, 27 mg of product, 70% yield); $R_f = 0.60$ (50% EtOAc in hexane); **^1H NMR** (100 MHz, $\text{DMSO}-d_6$) 11.02 (s, 1H), 10.65 (s, 1H), 7.96 - 7.95 (m, 1H), 7.50 (t, $J = 6.7$ Hz, 2H), 7.32 (d, $J = 8.3$ Hz, 1H), 7.04 (t, $J = 7.6$ Hz, 1H), 6.92 - 6.87 (m, 2H), 6.70 (d, $J = 2.7$ Hz, 1H), 4.95 (s, 1H), 3.92 - 3.79 (m, 4H), 3.34 (s, 3H), 0.87 (t, $J = 7.1$ Hz, 3H), 0.71 (t, $J = 7.1$ Hz, 3H); **^{13}C NMR** (100 MHz, $\text{DMSO}-d_6$) δ 177.5, 167.3, 166.7, 142.9, 137.3, 132.6, 131.8, 129.8, 125.0, 124.7, 121.7, 121.6, 119.1, 113.3, 112.2, 112.0, 111.1, 61.7, 61.1, 56.4, 53.6, 13.7, 13.6; **IR** (film) ν_{\max} 3381, 2982, 1715, 1471, 1371, 1299, 1246, 1189, 1031, 860, 816, 741 cm^{-1} ; **HRMS** (ESI) m/z $[M + Na]^+$ Calcd for $[C_{23}H_{21}BrN_2O_5+Na]^+$ 507.0526; Found 507.0530; **MP** 180 - 182 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak IB column; solvent: hexane/2-propanol = 70/30; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 6.00 min, t_R major = 11.09 min. $[\alpha]_D^{25.0} = +180.7$ ($c = 0.17$, CHCl_3 for 88% ee).




Dibenzy (R)-2-(3-(5-methoxy-1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (R)-**4j** was obtained as a colorless solid (0.08 mmol scale of reaction, 36 mg of product, 80% yield); R_f = 0.57 (50% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.05 (s, 1H), 8.95 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.23 - 7.14 (m, 4H), 7.16 - 7.09 (m, 3H), 7.08 (d, J = 2.5 Hz, 1H), 7.03 - 6.92 (m, 3H), 6.87 - 6.78 (m, 2H), 6.76 (d, J = 7.7 Hz, 1H), 6.72 (dd, J = 8.8, 2.5 Hz, 1H), 6.63 (d, J = 2.8 Hz, 1H), 5.24 (s, 1H), 4.91 - 4.68 (m, 4H), 3.62 (s, 3H), 2.36 (Water); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$) δ 178.1, 167.1, 166.7, 153.5, 142.1, 134.8, 134.6, 132.0, 129.4, 128.4, 128.2, 128.1, 127.9, 127.8, 127.7, 127.7, 127.2, 125.1, 124.9, 121.7, 112.3, 111.9, 111.4, 109.7, 103.0, 67.0, 66.7, 56.3, 55.4, 53.3; **IR** (film) ν_{max} 3377, 2355, 1713, 1615, 1469, 1308, 1214, 1146, 735 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{34}\text{H}_{28}\text{N}_2\text{O}_6 + \text{Na}]^+$ 583.1840; Found 583.1855; **MP** 158 - 160 $^\circ\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 60/40; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 5.60 min, t_R major = 16.12 min. $[\alpha]_D^{22.5} = +70.0$ (c = 0.10, MeOH for 96% ee).




Dibenzy (R)-2-(5-bromo-3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (R)-**4k** was obtained as a yellow solid (0.08 mmol scale of reaction, 36 mg of product, 74% yield); R_f = 0.60 (40% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.66 - 9.64 (m, 2H), 7.99 - 7.96 (m, 1H), 7.79 - 7.74 (m, 1H), 7.29 - 7.16 (m, 5H), 7.13 - 7.01 (m, 4H), 6.99 - 6.88 (m, 3H), 6.71 - 6.67 (m, 2H), 6.62 - 6.58 (m, 1H), 6.54 - 6.51 (m, 1H), 5.23 - 5.20 (m, 1H), 4.84 - 4.82 (m, 2H), 4.74 - 4.72 (m,


2H), ; ^{13}C NMR (125 MHz, DMSO) δ 177.6, 167.1, 166.6, 141.8, 137.2, 134.8, 134.7, 131.7, 131.4, 129.9, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 127.6, 124.8, 124.5, 121.8, 121.7, 119.4, 114.0, 111.6, 111.4, 67.2, 66.9, 56.4, 53.7; **IR** (film) ν_{max} 3388, 3066, 2924, 2854, 2840, 1728, 1620, 1471, 1465, 1442, 1311, 1273, 1250, 1217, 1145, 750, 686 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{33}\text{H}_{25}\text{BrN}_2\text{O}_5 + \text{Na}]^+$ 631.0839; Found 631.0839; **MP** 220 - 222 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 60/40; flow rate: 1.0 mL/min; detection: at 254 nm): t_{R} minor = 6.18 min, t_{R} major = 13.88 min. $[\alpha]_{\text{D}}^{25.0} = +120.0$ ($c = 0.16$, CHCl_3 for 94% ee).



Dibenzyl (R)-2-(3-(5-bromo-1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4I** was obtained as a colorless solid (0.08 mmol scale of reaction, 38 mg of product, 80% yield); $R_f = 0.55$ (50% EtOAc in hexane); ^1H NMR (400 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.85 (br, 1H), 9.41 (br, 1H), 7.98 (s, 1H), 7.83 - 7.81 (m, 1H), 7.1 - 7.08 (m, 9H), 6.95 - 6.91 (m, 3H), 6.7 - 6.73 (m, 3H), 6.5 - 6.53 (m, 1H), 5.16 (s, 1H), 4.81 - 4.72 (m, 4H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 178.1, 167.2, 166.7, 142.4, 142.4, 135.9, 134.8, 134.7, 129.2, 128.4, 128.3, 128.1, 127.9, 127.7, 126.9, 126.6, 126.1, 124.5, 124.3, 121.8, 113.2, 112.7, 111.5, 110.1, 67.2, 66.9, 56.5, 53.4; **IR** (film) ν_{max} 3391, 2925, 2257, 1728, 1621, 1471, 1379, 1312, 1266, 1147, 1025, 1005, 755, 698 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{33}\text{H}_{25}\text{BrN}_2\text{O}_5 + \text{Na}]^+$ 631.0839; Found 631.0867; **MP** 110 - 112 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 60/40; flow rate: 1.0 mL/min; detection: at 254 nm): t_{R} minor = 4.65 min, t_{R} major = 9.13 min. $[\alpha]_{\text{D}}^{25.2} = +200.0$ ($c = 0.18$, MeOH for 92% ee).




Diethyl (R)-2-(3-(1H-indol-3-yl)-2-oxo-5-phenylindolin-3-yl)malonate: Compound (*R*)-**4m** was obtained as a brown solid (0.08 mmol scale of reaction, 28 mg of product, 74% yield); $R_f = 0.55$ (40% EtOAc in hexane); $^1\text{H NMR}$ (500 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.72 - 9.68 (m, 2H), 8.29 - 8.28 (m, 1H), 7.86 - 7.85 (m, 1H), 7.61 - 7.48 (m, 3H), 7.42 - 7.35 (m, 2H), 7.31 - 7.24 (m, 2H), 7.06 - 6.97 (m, 3H), 6.73 - 6.71 (m, 1H) 5.21 (s, 1H), 3.94 - 3.83 (m, 4H), 2.73 (Water), 0.92 - 0.87 (m, 3 H), 0.78 - 0.75 (m, 3H); $^{13}\text{C NMR}$ (125 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 178.6, 167.4, 167.0, 142.1, 141.1, 137.2, 134.7, 130.6, 128.6, 127.2, 126.6, 126.5, 125.5, 125.1, 124.4, 121.9, 121.5, 119.1, 111.5, 110.0, 61.4, 60.8, 56.6, 53.7, 13.4, 13.2; **IR** (film) ν_{max} 3394, 3062, 2926, 2357, 1720, 1624, 1473, 1307, 1236, 827, 746 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{29}\text{H}_{27}\text{N}_2\text{O}_5]^+$ 483.1914; Found 483.1906; **MP** 180 - 182 $^\circ\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 6.56 min, t_R major = 8.17 min. $[\alpha]_D^{24.2} = +109.0$ ($c = 0.21$, MeOH for 91% ee).




Diethyl (R)-2-(3-(1H-indol-3-yl)-5-(3-methoxyphenyl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4n** was obtained as a colorless solid (0.08 mmol scale of reaction, 31 mg of product, 77% yield); $R_f = 0.56$ (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, 0.5 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) δ 9.72 (brs, 1H), 9.68 (brs, 1H), 8.08 (s, 1H), 7.65 (d, $J = 8.1$ Hz, 1H), 7.33 (d, $J = 7.6$ Hz, 1H), 7.16 - 7.08 (m, 2H), 6.701 - 6.99 (m, 1H), 6.94 (s, 1H), 6.89 - 6.86 (m, 1H) 6.82 - 6.80 (m, 2H), 6.67 - 6.65 (m, 1H), 6.55 (s, 1H), 5.00 (s, 1H), 3.75 - 3.67 (m, 7H), 2.65 (Water), 0.75 - 0.72 (m, 3H), 0.61 - 0.57(m, 3H); $^{13}\text{C NMR}$


(100 MHz, 0.5 mL CDCl₃, 0.1 mL DMSO-D₆) δ 178.5, 167.3, 166.9, 159.8, 142.6, 142.4, 137.2, 130.4, 130.6, 129.6, 127.2, 125.8, 120.5, 124.4, 121.9, 121.4, 119.2, 118.9, 112.5, 111.8, 111.7, 111.4, 109.9, 61.3, 60.7, 56.6, 55.2, 53.7, 13.4, 13.3; **IR** (film) ν_{\max} 3415, 2924, 2852, 1726, 1622, 1481, 1307, 1174, 1029, 848, 748 cm⁻¹; **HRMS** (ESI) m/z [M + H]⁺ Calcd for [C₃₀H₂₉N₂O₆]⁺ 513.2020; Found 513.2022; 513.2020; **MP** 270 - 272 °C; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak ID-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 5.05 min, t_R major = 6.26 min. $[\alpha]_D^{24.2} = +250.0$ ($c = 0.10$, CHCl₃ for 88% ee).



Diethyl (R)-2-(3-(1H-indol-3-yl)-5,7-dimethyl-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4o** was obtained as a colorless solid (0.08 mmol scale of reaction, 27 mg of product, 79% yield); $R_f = 0.56$ (40% EtOAc in hexane); **¹H NMR** (500 MHz, 0.5 mL CDCl₃, 0.1 mL DMSO-D₆) δ 9.47 - 9.45 (m, 2H), 7.74 - 7.72 (m, 1H), 7.48 (s, 1H), 7.12 - 7.08 (m, 1H), 6.93-6.84 (m, 2H), 6.75 - 6.74 (m, 1H), 6.51 - 6.50 (m, 1H), 5.01 (s, 1H), 3.77 - 3.67 (m, 4H), 2.56 (Water), 2.17 (s, 3H), 2.02 (s, 3H); **¹³C NMR** (125 MHz, 0.5 mL CDCl₃, 0.1 mL DMSO-D₆) δ 179.1, 167.4, 167.1, 138.5, 137.1, 130.8, 130.3, 129.5, 125.1, 125.0, 124.5, 122.2, 121.4, 118.6, 112.3, 111.3, 61.2, 60.7, 56.5, 54.0, 21.2, 16.5, 13.2 (2c); **IR** (film) ν_{\max} 3444, 3386, 2920, 2848, 1707, 1624, 1456, 1261, 1103, 744 cm⁻¹; **HRMS** (ESI) m/z [M + H]⁺ Calcd for [C₃₀H₂₉N₂O₆]⁺ 457.1734; Found 457.1749; **MP** 190 - 192 °C; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak ID-3 column; solvent: hexane/2-propanol = 70/30; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 7.09 min, t_R major = 10.79 min. $[\alpha]_D^{24.5} = +45.2$ ($c = 0.30$, MeOH for 90% ee).




Diethyl (R)-2-(5-chloro-3-(1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4p** was obtained as a brown solid (0.08 mmol scale of reaction, 25 mg of product, 70% yield); $R_f = 0.55$ (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.33 (s, 1H), 8.09 (d, $J = 2.6$ Hz, 1H), 8.05 (d, $J = 2.2$ Hz, 1H), 7.87 (d, $J = 8.0$ Hz, 1H), 7.25 (d, $J = 3.6$ Hz, 1H), 7.24 – 7.23 (m, 1H), 7.15 – 7.05 (m, 2H), 6.76 (d, $J = 8.3$ Hz, 1H), 6.62 (d, $J = 2.7$ Hz, 1H), 5.19 (s, 1H), 4.00 – 3.84 (m, 4H), 0.90 (t, $J = 7.1$ Hz, 3H), 0.77 (t, $J = 7.1$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 178.3, 167.3, 166.8, 140.4, 137.0, 131.5, 128.8, 127.8, 127.7, 124.8, 124.1, 122.4, 122.1, 119.9, 111.9, 111.4, 110.8, 61.9, 61.2, 56.4, 53.9, 13.5, 13.3; **IR** (film) ν_{max} 3389, 2990, 1721, 1620, 1461, 1381, 1289, 1256, 1159, 1011, 870, 800, 761, 720 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{23}\text{H}_{22}\text{ClN}_2\text{O}_5]^+$ 441.1212; Found 441.1236; **MP** 192 – 194 $^\circ\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 70/30; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 5.10 min, t_R major = 7.48 min. $[\alpha]_D^{24.5} = +201.8$ ($c = 0.10$, MeOH for 86% ee).




Dibenzyl (R)-2-(3-(1H-indol-3-yl)-5,7-dimethyl-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4q** was obtained as a colourless solid (0.08 mmol scale of reaction, 34 mg of product, 78% yield); $R_f = 0.61$ (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 10.11 (s, 1H), 9.51 (s, 1H), 6.80 (d, $J = 8.2$ Hz, 1H), 6.51 – 6.30 (m, 8H), 6.23 – 6.18 (m, 3H), 6.08 – 5.97 (m, 4H), 5.77 (s, 1H), 4.29 (s, 1H), 4.12 – 4.01 (m, 4H), 1.31 (s, 3H), 1.28 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, $\text{DMSO}-d_6$) δ 182.9, 172.1, 171.7, 144.1, 143.8, 142.2, 140.3, 140.2, 135.5, 134.9, 134.5, 133.5, 133.4, 133.2, 132.9, 132.7, 132.6, 130.0, 129.9, 126.7, 126.3, 123.8, 123.6, 116.9, 116.7, 71.8, 71.5, 61.5, 58.4, 26.1, 21.7; **IR**


(film) ν_{\max} 3385, 3064, 2924, 2854, 1718, 1612, 1471, 1465, 1311, 1273, 1217, 1155, 742, 696 cm^{-1} ; **HRMS** (ESI) m/z $[M + Na]^+$ Calcd for $[C_{35}H_{30}N_2O_5+Na]^+$ 581.2047; Found 581.2064; **MP** 201 - 203 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak AD-H column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 29.05 min, t_R major = 35.36 min. $[\alpha]_D^{25.0} = +45.9$ ($c = 0.40$, MeOH for 93% ee).



Dibenzy (R)-2-(3-(6-bromo-1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (*R*)-**4r** was obtained as a yellow solid (0.08 mmol scale of reaction, 23 mg of product, 92% yield; $R_f = 0.60$ (40% EtOAc in hexane); ^1H NMR (400 MHz, DMSO- D_6) δ 11.14 (s, 1H), 10.53 (s, 1H), 7.73 (d, $J = 7.6$ Hz, 1H), 7.64 (d, $J = 8.7$ Hz, 1H), 7.55 (s, 1H), 7.37 - 7.30 (m, 2H), 7.29 - 7.28 (m, 2H), 7.22 (d, $J = 7.1$ Hz, 1H), 7.16 (t, $J = 7.4$ Hz, 2H), 7.06 - 6.98 (m, 4H), 6.88 (d, $J = 7.8$ Hz, 1H), 6.77 (d, $J = 7.4$ Hz, 2H), 6.67 (s, 1H), 5.12 (s, 1H), 5.00 - 4.80 (m, 4H); ^{13}C NMR (100 MHz, DMSO- D_6) δ 177.7, 167.3, 166.7, 143.3, 138.4, 135.5, 135.5, 129.7, 129.2, 128.8, 128.6, 128.5, 128.3, 127.9, 127.8, 126.9, 126.2, 124.2, 123.7, 122.1, 121.8, 114.9, 114.6, 112.1, 110.3, 67.1, 66.8, 56.5, 53.2; **IR** (film) ν_{\max} 3455, 3364, 2994, 2830, 1717, 1622, 1491, 1409, 1301, 1221, 1210, 1100, 772, 636 cm^{-1} ; **HRMS** (ESI) m/z $[M + Na]^+$ Calcd for $[C_{33}H_{25}BrN_2O_5+Na]^+$ 631.0835; Found 631.0839; **MP** 195 - 197 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak ID-3 column; solvent: hexane/2-propanol = 60/40; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 7.18 min, t_R major = 10.29 min. $[\alpha]_D^{22.2} = +95.9$ ($c = 0.18$, CH_2Cl_2 for 98% ee).




Dibenzy (R)-2-(3-(7-iodo-1H-indol-3-yl)-2-oxoindolin-3-yl)malonate: Compound (R)-**4s** was obtained as a yellow solid (0.08 mmol scale of reaction, 44 mg of product, 85% yield); R_f = 0.63 (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, DMSO- D_6) δ 8.0 (s, 1H), 7.9 (d, J = 7.6 Hz, 1H), 7.9 (s, 1H), 7.8 (d, J = 8.2 Hz, 1H), 7.5 (d, J = 7.5 Hz, 1H), 7.25 – 7.14 (m, 7H), 7.06 – 7.00 (m, 3H), 6.84 – 6.78 (m, 3H), 6.69 (d, J = 7.7 Hz, 1H), 6.64 (d, J = 2.7 Hz, 1H), 5.27 (s, 1H), 4.95 – 4.86 (m, 4H); $^{13}\text{C NMR}$ (100 MHz, DMSO- D_6) δ 177.9, 167.1, 166.6, 141.5, 138.4, 134.9, 134.6, 131.0, 129.0, 128.9, 128.4, 128.3, 128.2, 128.2, 128.1, 128.0, 127.3, 125.1, 124.6, 122.5, 122.3, 121.7, 114.1, 110.0, 76.9, 67.4, 67.1, 56.5, 53.6; **IR** (film) ν_{max} 3443, 3364, 2994, 2804, 1719, 1622, 1441, 1400, 1301, 1290, 1200, 1105, 792, 606 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{33}\text{H}_{26}\text{IN}_2\text{O}_5]^+$ 657.0881; Found 657.0853; **MP** 150 - 152 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak IC-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 4.93 min, t_R major = 6.44 min. $[\alpha]_D^{20.6}$ = +243.2 (c = 0.15, CH_2Cl_2 for 90% ee).




(+)-Diethyl 2-(3-(6-hydroxybenzo[d][1,3]dioxol-5-yl)-2-oxoindolin-3-yl)malonate: Compound (+)-**4t** was obtained as a colourless solid (0.08 mmol scale of reaction, 31 mg of product, 90% yield); R_f = 0.52 (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, Chloroform- d) δ 9.90 (s, 1H), 8.74 (s, 1H), 8.01 (d, J = 7.2 Hz, 1H), 7.30 (td, J = 7.7, 1.3 Hz, 1H), 7.16 (td, J = 7.7, 1.2 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1H), 6.51 (s, 1H), 6.32 (s, 1H), 5.80 (dd, J = 20.8, 1.5 Hz, 2H), 5.33 (s, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.82 (qd, J = 7.1, 4.7 Hz, 2H), 1.09 (t, J = 7.1 Hz, 3H), 0.85 (t, J = 7.1 Hz, 3H); $^{13}\text{C NMR}$ (101 MHz,

Chloroform-*d*) δ 182.0, 167.2, 166.6, 152.4, 148.5, 141.6, 140.7, 129.5, 128.3, 123.5, 113.6, 110.7, 108.7, 101.9, 101.3, 61.8, 61.5, 57.8, 54.4, 13.3, 13.4; **IR** (film) ν_{\max} 3355, 3264, 2920, 2884, 1719, 1622, 1451, 1465, 1311, 1273, 1217, 1155, 742, 696 cm^{-1} ; **HRMS** (ESI) m/z $[M + H]^+$ Calcd for $[\text{C}_{22}\text{H}_{22}\text{NO}_8]^+$ 428.1340; Found 428.1331; **MP** 135 - 137 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak AD-H column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 7.17 min, t_R major = 24.25 min. $[\alpha]_D^{23.1} = +34.2$ ($c = 0.16$, MeOH for 50% ee).




Synthetic procedure for the synthesis of compound (R)-8: To a stirred solution of (R)-4f (300 mg, 0.6 mmol; 1.0 equiv) in DMSO (5 mL) at 25 $^{\circ}\text{C}$ was added lithium chloride (96 mg, 2.3 mmol, 4.0 equiv) and H_2O (104 μL , 5.6 mmol, 10.0 equiv). After 5 minutes stirring, the reaction mixture was transferred to a pre-heated oil bath (140 $^{\circ}\text{C}$) and stirring was continued for 24 h. After complete consumption of starting material (as judged by running TLC), reaction mixture was cooled down to 25 $^{\circ}\text{C}$ and quenched with water (4 mL). The organic compound was extracted with ethyl acetate (2 X 10 mL). Then the combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude material was purified by column chromatography by using 20 - 30 % (EtOAc/Hexane) to afford compound (R)-8 as a colorless solid.




Benzyl (R)-2-(3-(1H-indol-3-yl)-2-oxoindolin-3-yl)acetate: Compound (R)-8 was obtained as a yellow solid (0.6 mmol scale of reaction, 195 mg of product, 80% yield); $R_f = 0.45$ (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 11.08 (s, 1H), 10.56

(s, 1H), 7.35 - 7.21 (m, 10H), 7.18 - 7.11 (m, 3H), 7.03 - 6.99 (m, 2H), 6.95 - 6.90 (m, 2H), 6.80 (t, $J = 7.5$ Hz, 1H), 4.92 (s, 3H), 3.63 (d, $J = 16.0$ Hz, 1H), 3.51 (d, $J = 16.1$ Hz, 2H), 3.44 (Water); ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.4, 169.9, 143.3, 137.2, 136.3, 133.1, 128.8, 128.6, 128.3, 128.1, 125.1, 124.4, 124.0, 121.8, 121.6, 119.8, 119.1, 114.2, 112.1, 109.9, 65.9, 49.8; **IR** (film) ν_{max} 3415, 3310, 2929, 2802, 1728, 1642, 1619, 1480, 1327, 1154, 1059, 878, 760 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $[\text{C}_{25}\text{H}_{20}\text{N}_2\text{O}_3 + \text{Na}]^+$ 419.1366; Found 419.1380; **MP** 165 - 167 $^{\circ}\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_{R} minor = 5.71 min, t_{R} major = 13.53 min. $[\alpha]_{\text{D}}^{21.0} = +122.0$ ($c = 0.24$, MeOH for 99% ee).




Synthetic procedure for compound (R)-9: Compound (R)-8 (200 mg, 0.5 mmol; 1.0 equiv) was taken in dimethyl sulfoxide (3 mL) under nitrogen atmosphere. The reaction mixture was cooled to 0 $^{\circ}\text{C}$ and potassium *tert*-butoxide (119 mg, 1.1 mmol, 2.2 equiv) was added to it. After 5 min of stirring, methyl iodide (66 μL , 1.1 mmol, 2.2 equiv) was added at same temperature and stirring was continued for 3 h. Upon completion of starting material (as judged by running TLC), the reaction mixture was quenched with careful addition of water (2 mL) and organic compound was extracted with ethyl acetate (2 X 10 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude material was purified by column chromatography by using 20-30 % (EtOAc/Hexane) to afford compound (R)-9 as a white solid.




Benzyl (R)-2-(1-methyl-3-(1-methyl-1H-indol-3-yl)-2-oxoindolin-3-yl)acetate:

Compound (*R*)-**9** was obtained as a brown solid (0.5 mmol scale of reaction, 191 mg of product, 94% yield); $R_f = 0.53$ (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, CDCl_3) 7.30 - 7.28 (m, 3H), 7.09 - 7.04 (m, 6H), 6.85 - 6.81 (m, 2H), 6.52 (d, $J = 7.8$ Hz, 1H), 6.47 (d, $J = 7.8$ Hz, 1H), 4.89 - 4.81 (m, 2H), 4.37 (d, $J = 16.7$ Hz, 1H), 3.80 (s, 1H), 3.42 (d, $J = 16.8$ Hz, 1H), 3.13 (s, 3H), 3.05 (s, 3H); $^{13}\text{C NMR}$ (125 MHz) δ 177.8, 169.6, 144.4, 137.7, 135.3, 131.4, 128.6, 128.5, 128.4, 127.1, 125.5, 123.9, 122.4, 121.9, 120.8, 119.5, 112.9, 109.5, 108.3, 66.5, 49.7, 40.9, 32.7, 26.3; **IR** (film) ν_{max} 3415, 2924, 2852, 1726, 1622, 1481, 1307, 1174, 1029, 848, 748 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{27}\text{H}_{25}\text{N}_2\text{O}_3]^+$ 425.1860; Found 425.1883; **MP** 68 - 70 $^\circ\text{C}$; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak OD-3 column; solvent: hexane/2-propanol = 50/50; flow rate: 1.0 mL/min; detection: at 254 nm): t_R minor = 7.82 min, t_R major = 13.17 min. $[\alpha]_D^{24.1} = +12.5$ ($c = 0.19$, CHCl_3 for 99.5% ee).




Synthetic procedure for compound 10: Compound (*R*)-**9** (150 mg, 0.33 mmol; 1.0 equiv) was taken in acetic acid (3 mL) at 25 $^\circ\text{C}$. To this solution was added HCl (61 μL , 1.7 mmol, 5.0 equiv), followed by dimethyl sulfoxide (236 μL , 3.3 mmol, 10.0 equiv). Then the reaction mixture was placed over a pre-heated oil bath maintaining 50 $^\circ\text{C}$ for 3 h. Upon completion of starting material (as judged by running TLC), the reaction mixture was quenched with sat. Na_2CO_3 (2 mL) and organic compound was extracted with ethyl acetate (2 X 10 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude material was purified by

column chromatography by using 20-30% (EtOAc/Hexane) to afford compound **10** as an orange solid.




Benzyl 2-((3'R)-1,1'-dimethyl-2,2'-dioxo-[3,3'-biindolin]-3'-yl)acetate (10):

Compound **10** (major diastereomer) was obtained as a orange colour gel (0.3 mmol scale of reaction, 85 mg of product, 50% yield); $R_f = 0.44$ (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.29 - 7.29 (m, 3H), 7.10 - 7.05 (m, 6H), 6.84 (td, $J = 7.6, 1.4$ Hz, 1H), 6.52 (d, $J = 7.8$ Hz, 1H), 6.47 (d, $J = 7.8$ Hz, 1H), 4.89 - 4.81 (m 2H), 4.37 (dd, $J = 16.8, 1.3$ Hz, 1H), 3.80 (s, 1H), 3.44 - 3.39 (m, 1H), 3.13 (d, $J = 1.4$ Hz, 1H), 3.13 (s, 3H), 3.05 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 177.3, 174.7, 169.7, 144.0, 143.9, 135.3, 128.7, 128.6, 128.4, 128.1, 128.1, 126.8, 124.3, 123.6, 122.4, 122.1, 121.9, 107.9, 107.6, 66.3, 51.3, 49.6, 37.5, 25.9, 25.8; **IR** (film) ν_{max} 3425, 2914, 2862, 1721, 1612, 1482, 1317, 1124, 1009, 808, 758 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{27}\text{H}_{25}\text{N}_2\text{O}_4]^+$ 441.1809; Found 441.1810




Synthetic procedure for compound 11: Compound **10** (100 mg, 0.2 mmol; 1.0 equiv) was taken in toluene (2 mL) under nitrogen atmosphere at 0 °C. To this solution was added tetrabutyl ammonium hydrogen sulphate (16 mg, 0.05 mmol, 20 mol%), followed by 50% aq. sodium hydroxide (742 μL , 9.28 mmol, 40 equiv). After 5 minutes of stirring at 0 °C, bromoethyl acetate (53 μL , 0.5 mmol, 2.0 equiv) was added to the reaction mixture. Then the reaction mixture allowed stirring for 20 h at the same temperature. Upon completion of starting material (monitored by running TLC), the reaction mixture

was diluted with water (2 mL) and organic compound was extracted with ethyl acetate (2 X 10 mL). Then the organic layer was dried with anhydrous sodium sulphate and concentrated in *vacuo*. The crude material was purified by column chromatography by using 20-30% (EtOAc/Hexane) to afford compound **11** as an orange solid.




Benzyl 2-(3'-(2-ethoxy-2-oxoethyl)-1,1'-dimethyl-2,2'-dioxo-[3,3'-biindolin]-3-yl)acetate: Compound **11** was obtained as a colourless solid (0.22 mmol scale of reaction, 98 mg of product, 85% yield); $R_f = 0.53$ (40% EtOAc in hexane); $^1\text{H NMR}$ (700 MHz) δ 7.19 - 7.17 (m, 3H), 6.96 - 6.91 (m, 2H), 6.31 - 6.29 (m, 1H), 6.20 - 6.19 (m, 1H), 4.68 - 4.62 (m, 2H), 4.02 (d, $J = 16.0$ Hz, 1H), 3.95 (d, $J = 16.0$ Hz, 1H), 3.73 - 3.64 (m, 2H) 3.18 (d, $J = 16.0$ Hz, 1H), 3.11 (d, $J = 16.0$ Hz, 1H), 3.00 (s, 3H), 0.83 (d, $J = 7.11$ Hz, 3H); $^{13}\text{C NMR}$ (175 MHz) δ 176.6, 176.4, 169.7, 169.6, 143.8, 143.7, 135.2, 128.8, 128.7, 128.4, 128.3, 128.2, 126.8, 126.7, 122.8, 121.5, 121.4, 107.5, 107.3, 77.2, 77.1, 76.8, 66.4, 60.4, 52.5, 52.4, 33.9 (2C), 25.8, 25.5, 13.7; **IR** (film) ν_{max} 3446, 3435, 2956, 2922, 2850, 2350, 2090, 1735, 1712, 1612, 1494, 1456, 1338, 1188, 1118, 1095, 906, 754 cm^{-1} ; **HRMS** (ESI) m/z $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{23}\text{H}_{21}\text{N}_2\text{O}_6]^+$ 549.1996; Found 549.2013; **MP** 135 - 137 $^{\circ}\text{C}$.




Synthetic procedure for the synthesis of compound (3S,3S)-12: Compound **11** (50 mg, 0.1 mmol; 1.0 equiv) was taken in diethyl ether (2 mL) under nitrogen atmosphere at 0 $^{\circ}\text{C}$. To this solution was added LiBH_4 (225 μL , 0.45 mmol, 5.0 equiv) followed by

methanol (44 μ L, 0.9 mmol, 10.0 equiv). Then the reaction mixture allowed stirring for 1 h at the same temperature. Upon completion of starting material (monitored by running TLC), the reaction mixture was quenched with water (2 mL) and organic compound was extracted with ethyl acetate (2 X 5 mL). Then the organic layer was dried with anhydrous sodium sulphate and concentrated in *vacuo*. The crude material was purified by column chromatography by using 80 - 90% (EtOAc/Hexane) to afford compound (S,S)-**12** as a white crystalline solid.




(3S,3S)-Bis(2-hydroxyethyl)-1,1'-dimethyl-[3,3'-biindoline]-2,2'-dione: Compound (3S, 3'S)-**12** was obtained as a colourless solid (0.1 mmol scale of reaction, 33 mg of product, 88% yield); R_f = 0.20 (in EtOAc); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.03-6.99 (m, 4H), 6.81 (t, J = 7.5 Hz, 2H), 6.39 (d, J = 7.7 Hz, 2H), 3.42-3.36 (m, 2H), 3.22-3.17 (m, 2H), 3.13-3.06 (m, 2H), 3.03 (s, 6H), 2.63-2.55 (m, 2H); $^{13}\text{C NMR}$ (175 MHz) δ 178.1, 143.4, 128.4, 127.2, 123.5, 121.5, 107.5, 59.7.8, 54.9, 31.4, 25.7; Enantiomeric excess of pure compound was determined *via* HPLC analysis using a Chiralpak AD-3 column; solvent: 2-propanol /hexane= 30/80; flow rate: 1.0 mL/min; detection: at 254 nm): t_R major = 16.66 min. t_R minor = 20.41 min. $[\alpha]_D^{23.0} = -145.2$ (c = 0.4, CHCl_3 for 99.5% ee).




Synthesis of compound (±)-17 from enantioselective method: An oven dried sample vial was charged with Cu(OTf)_2 (0.1 equiv) and $t\text{Bu-PHOX}$ (0.2 equiv) in dichloromethane (4 mL) at 25 $^\circ\text{C}$ under nitrogen atmosphere. The reaction mixture was stirred for 30 minutes to make the complex. After that the reaction vessel was cooled to -

5 °C and *tert*-Butyl acetoacetate (3.0 equiv) was added to the mixture and stirring was continued for 15 minutes maintaining temperature -5 °C. Then, a solution of 3-hydroxy 2-oxindole in dichloromethane (0.5 mL) was added slowly to the reaction mixture. Then the reaction mixture was allowed to stir for 4 h at -5 °C. After complete consumption of starting material (as judged by running TLC), the crude mixture was concentrated under reduced pressure and purified by column chromatography by using 20-30% EtOAc-hexane mixture as eluent to afford the desired compound.




***tert*-Butyl-2-(3-(1*H*-indol-3-yl)-2-oxoindolin-3-yl)-3-oxobutanoate:** Compound (±)-**17** was obtained as a colourless solid (0.08 mmol scale of reaction, 31 mg of product, 95% yield); dr = 1.1:1 (determined from un purified reaction mixture] of (±)-**17**; R_f = 0.51 (40% EtOAc in hexane); $^1\text{H NMR}$ (400 MHz, CDCl_3 , spectrum contains ~1.1:1 diastereomers) δ 8.57 (d, J = 9.4, 1H for minor diastereomer), 8.44 (d, J = 8.7, 1H for major diastereomer), 8.20 – 8.17 (m, 2H for major + minor diastereomers), 8.06 - 8.02 (m, 2H for major + minor diastereomers), 7.93 (d, J = 7.5, 1H for major diastereomer), 7.85 (d, J = 7.5, 1H for minor diastereomer), 7.25 - 7.16 (m, 4H), 7.16 - 6.99 (m, 6H for major + minor diastereomers), 6.81 - 6.76 (m, 2H for major + minor diastereomers), 6.52 (s, 1H for minor diastereomer), 6.41 (s, 1H for major diastereomer), 5.43 (s, 1H for major diastereomer), 5.07 (s, 1H for minor diastereomer), 2.08 - 2.04 (m, 7H for major + minor diastereomers), 1.04 - 1.02 (m, 9H for major diastereomer), 0.99 (s, 9H for minor diastereomer) $^{13}\text{C NMR}$ (100 MHz, CDCl_3 , spectrum contains ~1.1:1 diastereomers) δ 202.5, 201.5, 179.4, 178.9, 168.1, 166.7, 141.8, 141.5, 137.2, 137.1, 130.4, 130.1, 128.5, 128.4, 128.0, 126.5, 125.4 (two carbons), 124.9, 124.4, 122.6 (two carbons), 122.4, 122.1 (two carbons), 122.1, 121.7 (two carbons), 119.7, 119.6, 111.8, 111.3, 110.1, 109.8, 83.1, 81.9, 65.0, 61.4, 54.2, 53.5, 32.4, 29.3, 27.2, 27.2, 27.1; **IR** (film) ν_{max} 3455, 3364, 3220, 2884, 2019, 1722, 1711, 1665, 1461, 1223, 1207, 1185, 702, 606 cm^{-1} ; **HRMS** (ESI) m/z

$[M + Na]^+$ Calcd for $[C_{24}H_{24}N_2O_4 + Na]^+$ 427.1628; Found 427.1606; **MP** 120 - 122 °C; Enantiomeric peaks was determined *via* HPLC analysis using a Chiralpak OZ-3 column; solvent: hexane/2-propanol = 70/30; flow rate: 1.0 mL/min; detection: at 254 nm); in case of major diastereomer $t_{R1} = 4.93$ min, $t_{R2} = 17.01$ min. for 0% ee; in case of minor diastereomer $t_{R1} = 8.58$ min, $t_{R2} = 10.53$ min. for 0% ee.



Synthesis of compound (±)-19 from enantioselective method: An oven dried sample vial was charged with $Cu(OTf)_2$ (0.1 equiv) and $tBu-PHOX$ (0.2 equiv) in dichloromethane (4 mL) at 25 °C under nitrogen atmosphere. The reaction mixture was stirred for 30 minutes to make the complex. After that the reaction vessel was cooled to -5 °C and compound 18 (3.0 equiv) was added to the mixture and stirring was continued for 15 minutes maintaining temperature -5 °C. Then, a solution of 3-hydroxy 2-oxindole in dichloromethane (0.5 mL) was added slowly to the reaction mixture. Then the reaction mixture was allowed to stir for 6 h at -5 °C. After complete consumption of starting material (as judged by running TLC), the crude mixture was concentrated under reduced pressure and purified by column chromatography by using 30-40% EtOAc-hexane mixture as eluent to afford the desired compound.



Ethyl-1-(3-(1*H*-indol-3-yl)-2-oxoindolin-3-yl)-2-oxocyclopentane-1-carboxylate:


Compound (±)-**19** was obtained as a colourless solid (0.08 mmol scale of reaction, 25 mg of product, 80% yield); dr = 4.7:1 (determined from un purified reaction mixture] of (±)-**19**; $R_f = 0.31$ (40% EtOAc in hexane); 1H NMR (400 MHz, $CDCl_3$, spectrum contains ~4.7:1 diastereomers) δ 8.92 (s, 2H for major + minor diastereomers), 8.65 (s,


2H for major + minor diastereomers), 8.26 (s, 2H for major + minor diastereomers), 7.87 (s, 1H for minor diastereomer), 7.67 (s, 1H for major diastereomer), 7.31 - 6.96 (m, 12H for major + minor diastereomers), 6.73 (s, 2H for major + minor diastereomers), 4.06 - 3.74 (m, 4H for major + minor diastereomers), 3.15 - 2.94 (m, 4H for major + minor diastereomers), 2.63 - 2.28 (m, 4H for major + minor diastereomers), 2.00 - 1.76 (m, 4H for major + minor diastereomers), 1.06 - 0.64 (m, 6H for major + minor diastereomers); **¹³C NMR** (100 MHz, CDCl₃, spectrum contains ~4.7:1 diastereomers) δ 213.5, 212.8, 179.8, 179.0, 170.9, 170.2, 141.1, 141.1, 136.6, 136.5, 131.9, 131.6, 128.7, 128.6, 128.4, 128.3, 127.4, 127.3, 125.9, 125.8, 122.2, 121.8, 121.8, 121.7, 121.6, 121.3, 119.7, 119.6, 111.6, 110.6, 110.1, 109.7, 109.6, 109.1, 66.5, 66.3, 61.8, 61.7, 55.7, 55.7, 39.1, 38.7, 33.4, 33.1, 19.6, 19.4, 13.7, 13.5; **IR** (film) ν_{\max} 3545, 3334, 3210, 2980, 2119, 1742, 1721, 1645, 1601, 1423, 1287, 1285, 1002, 806 cm⁻¹; **HRMS** (ESI) m/z [M + Na]⁺ Calcd for [C₂₄H₂₂N₂O₄ + Na]⁺ 425.1472; Found 425.1460; **MP** 100 - 102 °C; Enantiomeric peaks was determined *via* HPLC analysis using a Chiralpak AS-3 column; solvent: hexane/2-propanol = 60/40; flow rate: 1.0 mL/min; detection: at 254 nm); in case of minor diastereomer t_{R1} = 5.24 min, t_{R2} = 12.72 min. for 0% ee; in case of major diastereomer t_{R1} = 7.11 min, t_{R2} = 21.71 min. for 0% ee.

References and notes:


1. Wang, C. H.; White, A. R.; Schwartz, S. N.; Alluri, S.; Cattabiani, T. M.; Zhang, L. K. Chan, T. M.; Buevich, A. V.; Ganguly, A. K. *Tetrahedron* **2012**, *68*, 9750.
2. Srihari, G.; Murthy, M. M. *Synth. Commun.* **2011**, *41*, 2684.
3. Prathima, P. S.; Ranjesh, P.; Rao, J. V.; Kailash, U. S.; Sridhar, B. *Eur. J. Med. Chem.* **2014**, *84*, 155.
4. Kinthada, L. K.; Babu, K. N.; Padhi, D.; Bisai, A. *Eur. J. Org. Chem.* **2017**, 3078.
5. Babu, K. N.; Kinthada, L. K.; Ghosh, S.; Bisai, A. *Org. Biomol. Chem.* **2015**, *13*, 10641.


Spectral Graphics

¹H NMR (400 MHz, CDCl₃) of compound **14**





¹H NMR (500 MHz, CDCl₃) of compound **15a**


¹H NMR (400 MHz, CDCl₃) of compound **15b**




^1H NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-\text{D}_6$) of compound **13b**




^{13}C NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL DMSO-D_6) of compound **13b**




¹H NMR (400 MHz, DMSO-D₆) of compound **(±)-5a**





^1H NMR (500 MHz, DMSO- D_6) of compound (\pm)-**5b**




^{13}C NMR (125 MHz, DMSO- D_6) of compound (±)-**5b**




¹H NMR (400 MHz, CDCl₃) of compound **(±)-5c**




^{13}C NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL DMSO-D_6) of compound (±)-**5c**





^1H NMR (400 MHz, DMSO- D_6) of compound **(±)-5d**




¹³C NMR (100 MHz, DMSO-D₆) of compound **(±)-5d**





^1H NMR (400 MHz, DMSO- D_6) of compound **(±)-5e**





^{13}C NMR (100 MHz, DMSO- D_6) of compound (±)-5e



 ^1H NMR (500 MHz, DMSO- D_6) of compound (\pm)-**5f**




^{13}C NMR (125 MHz, DMSO- D_6) of compound (±)-**5f**





¹H NMR (500 MHz, DMSO-D₆) of compound (±)-**5g**




^{13}C NMR (125 MHz, DMSO- D_6) of compound (±)-**5g**





¹H NMR (500 MHz, DMSO-D₆) of compound **(±)-5h**




¹³C NMR (125 MHz, DMSO-D₆) of compound (±)-5h



 ^1H NMR (500 MHz, DMSO- D_6) of compound (\pm)-**5i**




¹³C NMR (125 MHz, DMSO-D₆) of compound (±)-**5i**





¹H NMR (500 MHz, DMSO-D₆) of compound **(±)-5k**




^{13}C NMR (125 MHz, DMSO- D_6) of compound (±)-**5k**





^1H NMR (500 MHz, DMSO- D_6) of compound (±)-51



^{13}C NMR (125 MHz, DMSO- D_6) of compound (±)-**51**



¹H NMR (400 MHz, 0.5 mL CDCl₃, 0.1 mL DMSO-D₆) of compound **(R)-4a**



^{13}C NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL DMSO-D_6) of compound (R)-4a

Display Report


Analysis Info

Analysis Name D:\Data\user data\2015\MAY-2015\07-MAY-2015\Dr.A..Bisai-AB-KNB-02-124_1-B,6_01_2405.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A..Bisai-AB-KNB-02-124
Comment



Acquisition Date 5/7/2015 1:34:17 PM
Operator RUCHI
Instrument micrOTOF-Q II 10330

Acquisition Parameter



Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste



Scanned copy of mass spectrum of (R)-4a



¹H NMR (500 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-D₆) of compound (R)-4b



¹³C NMR (100 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-D₆) of compound **(R)-4b**

Display Report




Analysis Info

Analysis Name D:\Data\user data\2015\SEPTEMBER-2015\23-SEP-2015\Dr.A.Bisai-AB-KNB-03-006_1-A,6_01_3729.d
 Method HRLCMS-20 Sept.m
 Sample Name Dr.A.Bisai-AB-KNB-03-006
 Comment

Acquisition Date 9/23/2015 12:15:51 PM
 Operator RUCHI
 Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	130.0 Vpp	Set Divert Valve	Waste





Bruker Compass DataAnalysis 4.0



printed: 9/23/2015 12:47:06 PM

Page 1 of 1

Scanned copy of mass spectrum of (R)-4b



^1H NMR (400 MHz, CDCl_3) of compound (R)-4c



^{13}C NMR (100 MHz, CDCl_3) of compound (R)-4c

Display Report




Analysis Info



Analysis Name D:\Data\user data\2015\SEPTEMBER-2015\23-SEP-2015\Dr.A.Bisai-AB-KNB-03-002_1-A,5_01_3728.d
 Method HRLCMS-20 Sept tune wide.m
 Sample Name Dr.A.Bisai-AB-KNB-03-002
 Comment

Acquisition Date 9/23/2015 12:03:37 PM
 Operator RUCHI
 Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste





^1H NMR (400 MHz, CDCl_3) of compound (R)-4d



¹³C NMR (100 MHz, CDCl₃) of compound (R)-4d

Display Report




Analysis Info

Analysis Name D:\Data\user data\2015\AUGEST-2015\24-AUG-2015\Dr.A.Bisai-AB-KNB-02-254_1-A,7_01_3457.d
 Method HRLCMS-20 Sept tune wide.m
 Sample Name Dr.A.Bisai-AB-KNB-02-254
 Comment

Acquisition Date 8/24/2015 2:40:20 PM
 Operator RUCHI
 Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste





Bruker Compass DataAnalysis 4.0

printed: 8/24/2015 3:35:52 PM

Page 1 of 1

Scanned copy of mass spectrum of (R)-4d

 ^1H NMR (400 MHz, DMSO- D_6) of compound (+)-**4e**



^{13}C NMR (100 MHz, DMSO- D_6) of compound (+)-4e

Display Report




Analysis Info


Analysis Name D:\Data\user data\2015\SEPTEMBER-2015\09-SEPT-2015\Dr.A.Bisai-AB-KNB-02-255-2_1-A,8_01_3612.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-02-255-2
Comment



Acquisition Date 9/9/2015 2:57:01 PM
Operator RUCHI
Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste



 ^1H NMR (500 MHz, CDCl_3) of compound (*R*)-**4f**



^{13}C NMR (500 MHz, CDCl_3) of compound **(R)-4f**

Display Report




Analysis Info


Analysis Name D:\Data\user data\2015\AUGEST-2015\24-AUG-2015\Dr.A.Bisai-AB-KNB-02-248_1-A,8_01_3458.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-02-248
Comment


Acquisition Date 8/24/2015 2:52:29 PM
Operator RUCHI
Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste



¹H NMR (400 MHz, DMSO-D₆) of compound (*R*)-**4g**



¹³C NMR (100 MHz, DMSO-D₆) of compound **(R)-4g**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2015\SEPTMBER-2015\09-SEPT-2015\Dr.A.Bisai-AB-KNB-02-258-R3_1-B,1_01_3613.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-02-258-R3
Comment




Acquisition Date 9/9/2015 3:09:11 PM


Operator RUCHI

Instrument micrOTOF-Q II 10330


Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste





^1H NMR (500 MHz, DMSO- D_6) of compound **(R)-4h**



¹³C NMR (125 MHz, DMSO-D₆) of compound **(R)-4h**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2015\AUGEST-2015\26-AUG-2015\Dr.A.Bisai-AB-KNB-02-206_1-B,3_01_3483.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-02-206
Comment


Acquisition Date 8/26/2015 12:59:25 PM

Operator RUCHI

Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste




Bruker Compass DataAnalysis 4.0



printed: 8/26/2015 2:44:58 PM

Page 1 of 1

Scanned copy of mass spectrum of (R)-4h



¹H NMR (400 MHz, DMSO-D₆) of compound (R)-4i



¹³C NMR (100 MHz, DMSO-D₆) of compound **(R)-4i**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2015\AUGEST-2015\26-AUG-2015\Dr.A.Bisai-AB-KNB-02-205_1-B.2_01_3482.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-02-205
Comment




Acquisition Date 8/26/2015 12:47:16 PM



Operator RUCHI

Instrument microTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste





^1H NMR (0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-d_6$) of compound **(R)-4j**



^{13}C NMR (0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-\text{D}_6$) of compound (R)-**4j**

Display Report




Analysis Info



Analysis Name D:\Data\user data\2015\SEPTEMBER-2015\09-SEPT-2015\Dr.A.Bisai-AB-KNB-02-280_1-A,6_01_3610.d
 Method HRLCMS-20 Sept tune wide.m
 Sample Name Dr.A.Bisai-AB-KNB-02-280
 Comment

Acquisition Date 9/9/2015 2:32:38 PM
 Operator RUCHI
 Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste





^1H NMR (500 MHz, 0.4 mL CDCl_3 , 0.1 mL DMSO-D_6) of compound (R)-4k



^{13}C NMR (120 MHz, 0.4 mL CDCl_3 , 0.1 (R)-4k

Display Report

Analysis Info

Analysis Name D:\Data\user data\2017\MAY 2017\25 may\Dr A Bisai-KNB-02-324_1-E,4_01_1707.d
 Method hrlcms_pos_mid_tunemix.m
 Sample Name Dr A Bisai-KNB-02-324
 Comment




Acquisition Date 5/25/2017 11:01:27 AM

Operator RUCHI SHRIVASTAVA


Instrument micrOTOF-Q II 10330

Acquisition Parameter



Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste



Scanned copy of mass spectrum of (R)-4k



¹H NMR (400 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-D₆) of compound (R)-41



^{13}C NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL DMSO-D_6) of compound **(R)-41**

Display Report




Analysis Info

Analysis Name D:\Data\user data\2015\SEPTMBER-2015\09-SEPT-2015\Dr.A.Bisai-AB-KNB-02-279_1-A,7_01_3611.d
Method HRLCMS-20 Sept tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-02-279
Comment


Acquisition Date 9/9/2015 2:44:51 PM
Operator RUCHI
Instrument micrOTOF-Q II 10330

Acquisition Parameter



Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste



Scanned copy of mass spectrum of (R)-41



^1H NMR (500 MHz, 0.4 mL CDCl_3 , 0.1 mL DMSO-D_6) of compound **(R)-4m**



¹³C NMR (125 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-D₆) of compound **(R)-4m**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2016\July 2016\29-07-2016\Dr.A.Bisai-AB-KNB-03-302_1-B,2_01_7003.d
 Method hrlcms-pos_mid_tune wide.m
 Sample Name Dr.A.Bisai-AB-KNB-03-302
 Comment




Acquisition Date 7/29/2016 3:31:06 PM



Operator DIMPLE

Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste





¹H NMR (500 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-D₆) of compound **(R)-4n**



^{13}C NMR (100 MHz, 0.4 mL CDCl_3 , 0.1 mL $\text{DMSO}-\text{D}_6$) of compound (R)-4n

Display Report

Analysis Info

Analysis Name D:\Data\user data\2016\July 2016\29-07-2016\Dr.A.Bisai-AB-KNB-03-303_1-B.1_01_7002.d
Method hrlcms-pos_mid_tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-03-303
Comment




Acquisition Date 7/29/2016 3:18:56 PM



Operator DIMPLe



Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste







¹³C NMR (125 MHz, 0.4 mL CDCl₃, 0.1 mL DMSO-D₆) of compound **(R)-4o**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2017\MAY 2017\24 may\Dr.A. Bisai-AB-KNB-03-280.d

Method tune_wide.m

Sample Name AB-KNB-03-280




Comment


Acquisition Date 5/24/2017 4:29:39 PM

Operator RUCHI SHRIVASTAVA



Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type ESI
Focus Not active
Scan Begin 50 m/z
Scan End 3000 m/zIon Polarity Positive
Set Capillary 4500 V
Set End Plate Offset -500 V
Set Collision Cell RF 600.0 VppSet Nebulizer 0.4 Bar
Set Dry Heater 180 °C
Set Dry Gas 4.0 l/min
Set Divert Valve Waste



^1H NMR (500 MHz, 0.4 mL CDCl_3) of compound **(R)-4p**



^{13}C NMR (125 MHz, 0.4 mL CDCl_3) of compound (R)-4p

Display Report

Analysis Info

Analysis Name D:\Data\user data\2016\July 2016\29-07-2016\Dr.A.Bisai-AB-KNB-03-207_1-A,4_01_6991.d
Method hrlcms-pos_mid_tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-03-207
Comment




Acquisition Date 7/29/2016 1:11:26 PM


Operator DIMPLE

Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste





^1H NMR (400 MHz, DMSO-D_6) of compound **(R)-4q**



¹³C NMR (100 MHz, DMSO-D₆) of compound (*R*)-**4q**




Display Report

Analysis Info


Analysis Name	D:\Data\user data\2017\MAY 2017\24 may\Dr.A.Bisai-AB-KNB-03-310.d	Acquisition Date	5/24/2017 4:31:49 PM
Method	tune_wide.m	Operator	RUCHI SHRIVASTAVA
Sample Name	AB-KNB-03-310	Instrument	micrOTOF-Q II 10330
Comment			

Acquisition Parameter



Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste



Scanned copy of mass spectrum of (R)-4q



¹H NMR (400 MHz, DMSO-D₆) of compound (*R*)-**4r**



^{13}C NMR (100 MHz, DMSO- D_6) of compound **(R)-4r**

Display Report

Analysis Info

Analysis Name D:\Data\NEW USER DATA 2017\2018\May-2018\08-05-2018\Dr A Bisai-KNB-05-112-R_1-B,1_01_1628.d
Method hrlcms-20 sept.m
Sample Name Dr A Bisai-KNB-05-112-R
Comment




Acquisition Date 5/8/2018 12:26:17 PM

Operator RUCHI


Instrument micrOTOF-Q II 10330

Acquisition Parameter



Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	130.0 Vpp	Set Divert Valve	Waste



Mass spectrum of (R)-4r



^1H NMR (400 MHz, CDCl_3) of compound (R)-4s



^{13}C NMR (100 MHz, CDCl_3) of compound **(R)-4s**

Display Report




Analysis Info



Analysis Name D:\Data\NEW USER DATA 2017\2018\May-2018\11-05-2018\Dr A Bisai-KNB-05-122_1-B,8_01_1724.d
Method hrlcms-20 sept.m
Sample Name Dr A Bisai-KNB-05-122
Comment

Acquisition Date 5/11/2018 12:36:05 PM
Operator RUCHI
Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.2 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	7.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	130.0 Vpp	Set Divert Valve	Waste





^1H NMR (400 MHz, CDCl_3) of compound (+)-**4t**



^{13}C NMR (100 MHz, DMSO- D_6) of compound (+)-**4t**

Display Report




Analysis Info


Analysis Name D:\Data\user data\2017\JUNE 2017\03 JUNE\AB-KNB-060_1-A,8_01_1802.d
Method hrlcms_pos_mid_tunemix.m
Sample Name AB-KNB-060
Comment

Acquisition Date 5/5/2017 11:40:37 AM
Operator RUCHI SHRIVASTAVA
Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste





¹H NMR (400 MHz, DMSO-D₆) of compound (R)-**8**



^{13}C NMR (400 MHz, DMSO-D_6) of compound **(R)-8**

Display Report

Analysis Info




Analysis Name D:\Data\NEW USER DATA 2017\17 oct\Dr.A.BISAI-AB-KNB-03-168-R.d
Method tune_wide.m
Sample Name AB-KNB-03-168-R
Comment

Acquisition Date 10/17/2017 12:42:35 PM


Operator RUCHI
Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Waste



Scanned copy of mass spectrum of (R)-8

 ^1H NMR (400 MHz, CDCl_3) of compound (R)-9



^{13}C NMR (100 MHz, CDCl_3) of compound (*R*)-**9**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2016\July 2016\29-07-2016\Dr.A.Bisai-AB-KNB-03-170_1-A,5_01_6993.d
Method hrlcms-pos_mid_tune wide.m
Sample Name Dr.A.Bisai-AB-KNB-03-170
Comment




Acquisition Date 7/29/2016 1:31:50 PM



Operator DIMPLe

Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste





^1H NMR (400 MHz, CDCl_3) of compound **10**



¹³C NMR (100 MHz, CDCl₃) of compound **10**

Display Report




Analysis Info


Analysis Name D:\Data\user data\2017\JUNE 2017\19 june\Dr A Bisai-AB-KNB-03-174-CRUDE_1-B,8_01_2168.d
Method hrlcms_pos_mid_tunemix.m
Sample Name Dr A Bisai-AB-KNB-03-174-CRUDE
Comment



Acquisition Date 6/19/2017 3:26:42 PM
Operator RUCHI SHRIVASTAVA
Instrument micrOTOF-Q II 10330

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste



 ^1H NMR (400 MHz, CDCl_3) of compound **11**



^{13}C NMR (100 MHz, CDCl_3) of compound **11**

Display Report

Analysis Info

Analysis Name D:\Data\user data\2017\MAY 2017\25 may\Dr A Bisai-KNB-03-255_1-E,3_01_1706.d
Method hrlcms_pos_mid_tunemix.m
Sample Name Dr A Bisai-KNB-03-255
Comment




Acquisition Date 5/25/2017 10:53:18 AM

Operator RUCHI SHRIVASTAVA



Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Waste




Scanned copy of mass spectrum of 11







¹³C NMR (100 MHz, CDCl₃) of compound (3*S*, 3'*S*)-**12**



¹H NMR (400 MHz, CDCl₃) of compound (±)-17



¹³C NMR (100 MHz, CDCl₃) of compound (±)-17




Display Report

Analysis Info

Analysis Name	D:\Data\NEW USER DATA 2017\2018\15-march-2018\Dr. A Bisai-KNB-02-221.d	Acquisition Date	3/15/2018 10:13:15 AM
Method	tune mix_low.New.021117.m	Operator	RUCHI
Sample Name	KNB-02-221	Instrument	microTOF-Q II 10330
Comment			

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4600 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	100.0 Vpp	Set Divert Valve	Waste






Bruker Compass DataAnalysis 4.0

printed: 3/15/2018 10:15:34 AM

Page 1 of 1

Mass spectrum of (±)-17

 ^1H NMR (400 MHz, CDCl_3) of compound **(±)-19**



^{13}C NMR (100 MHz, CDCl_3) of compound (±)-**19**

Display Report

Analysis Info

Analysis Name D:\Data\NEW USER DATA 2017\2018\15-march-2018\Dr. A Bisai-KNB-02-217.d
Method tune mix_low.New.021117.m
Sample Name KNB-02-217
Comment




Acquisition Date 3/15/2018 10:54:55 AM

Operator RUCHI

Instrument micrOTOF-Q II 10330



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4600 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	100.0 Vpp	Set Divert Valve	Waste





Mass spectrum of (±)-19

Determination of diastereomeric ratio of compound **10 from ^1H NMR of crude reaction**





^1H NMR (400 MHz, CDCl_3) of crude compound **10**

Determination of diastereomeric ratio of compound (\pm)-17 from ^1H NMR of crude reaction

^1H NMR (400 MHz, CDCl_3) of crude compound (\pm)-17


Determination of diastereomeric ratio of compound **19 from ^1H NMR of crude reaction**




^1H NMR (400 MHz, CDCl_3) of crude compound **(±)-19**

HPLC Traces

HPLC data of compound-(±)-4a



Data File C:\CHEM32\1\DATA\NARESH\2018-02-1317-34-13AB-KNB-05-048-ID3-50-1-254-50MRAC.D
 Sample Name: AB-KNB-05-048-ID3-50-1-254-50MRAC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.043	VV	0.2780	4.92836e4	2457.59082	50.3397
2	6.270	MM	0.4505	4.86185e4	1798.77979	49.6603


Totals : 9.79021e4 4256.37061

*** End of Report ***

HPLC data of compound (R)-4a



Data File C:\CHEM32\...A\NARESH\2018-03-0615-14-36AB-KNB-05-048-ID3-50-1-254-50M-CHIRAL2.D
 Sample Name: AB-KNB-05-048-ID3-50-1-254-50M-CHIRAL2




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.887	MM	0.1947	1602.37219	137.17230	2.9103
2	5.920	BB	0.2606	5.34571e4	2878.73560	97.0897


Totals : 5.50595e4 3015.90790

*** End of Report ***

HPLC data of compound (R)-4a from 5k



Data File C:\CHEM32\...A\NARESH\2018-03-0616-21-47AB-KNB-05-048-ID3-50-1-254-50M-CHIRAL6.D
 Sample Name: AB-KNB-05-048-ID3-50-1-254-50M-CHIRAL6




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.888	BV	0.1812	6495.49609	494.67331	11.7701
2	5.933	VV	0.2605	4.86909e4	2599.23633	88.2299

Totals : 5.51864e4 3093.90964

*** End of Report ***

HPLC data of compound (\pm)-4b

Data File C:\CHEM32\1\DATA\NARESH\2018-03-0723-22-17AB-KNB-03-006-OZ3-30-1-254-50M.D
 Sample Name: AB-KNB-03-006-OZ3-30-1-254-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.499	BV	0.9274	1.24358e4	198.35529	50.7449
2	14.229	MM	1.6576	1.20707e4	121.37089	49.2551


Totals : 2.45066e4 319.72617

*** End of Report ***

HPLC data of compound (R)-4b



Data File C:\CHEM32\1\DATA\NARESH\2018-03-0718-32-53AB-KNB-05-055-OZ3-30-1-254-50M.D
 Sample Name: AB-KNB-05-055-OZ3-30-1-254-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.711	MM	1.0946	2362.91309	35.97766	5.4219
2	14.290	MM	1.6580	4.12177e4	414.34091	94.5781

Totals : 4.35806e4 450.31857

*** End of Report ***

HPLC data of compound (±)-4c

Data File C:\CHEM32\...TA\NARESH\2018-01-2614-07-11AB-KNB-02-E-001-IB-30-1-254-50 M RACE.D
 Sample Name: AB-KNB-02-E-001-IB-30-1-254-50 M RACE




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.486	MM	0.3911	7456.38379	317.74460	49.3869
2	6.354	MM	0.5032	7641.51709	253.08270	50.6131


Totals : 1.50979e4 570.82730

*** End of Report ***

HPLC data of compound (R)-4c



Data File C:\CHEM32\1\DATA\NARESH\2018-01-2614-47-16AB-KNB-02-E-001-IB-30-1-254-50 M CHI.D
 Sample Name: AB-KNB-02-E-001-IB-30-1-254-50 M CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.457	BV	0.3505	172.50580	7.43912	5.4415
2	6.324	VB	0.5144	2997.67676	83.58624	94.5585

Totals : 3170.18256 91.02535

*** End of Report ***

HPLC data of compound (\pm)-4d

Data File C:\CHEM32\1\DATA\NARESH\2018-02-1422-35-25AB-KNB-02-268-R-OD3-50-1-254-50M RAC.D
 Sample Name: AB-KNB-02-268-R-OD3-50-1-254-50M RAC



Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.784	BV	0.1911	2.91449e4	2311.79590	49.4875
2	6.864	VB	0.3448	2.97486e4	1310.78491	50.5125

Totals : 5.88935e4 3622.58081


=====

*** End of Report ***

HPLC data of compound (R)-4d



Data File C:\CHEM32\1\DATA\NARESH\2018-02-1422-19-51AB-KNB-02-268-R-OD3-50-1-254-50M CHI.D
 Sample Name: AB-KNB-02-268-R-OD3-50-1-254-50M CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.862	MM	0.2001	5895.59717	491.08658	11.5294
2	6.985	BBA	0.3270	4.52396e4	2119.83569	88.4706

Totals : 5.11352e4 2610.92227

*** End of Report ***

HPLC data of compound (\pm)-4e

Data File C:\CHEM32\1\DATA\NARESH\2017-10-1209-47-08AB-KNB-02-255-R-AD-H-50-1-254-50M.D
 Sample Name: AB-KNB-02-255-R-AD-H-50-1-254-50M



Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.852	BV	0.7148	1.04855e4	215.83139	20.1239
2	12.333	VB	1.0442	1.58338e4	228.56190	30.3886
3	18.633	BB	1.3373	1.03880e4	112.91732	19.9368
4	23.003	BB	1.8207	1.53972e4	126.08580	29.5507

Totals : 5.21044e4 683.39642

=====


*** End of Report ***

HPLC data of compound (R)-4e



Data File C:\CHEM32\1\DATA\NARESH\2017-10-1121-53-38AB-KNB-02-265-R2-AD-H-50-1-254-50M.D

Sample Name: AB-KNB-02-265-R2-AD-H-50-1-254-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.406	MM	0.6707	4361.21436	108.37340	3.9545
2	11.884	MM	0.8780	4355.54980	82.67854	3.9494
3	17.840	MM	1.5772	4.99243e4	527.54572	45.2686
4	22.057	VBA	1.9889	5.16434e4	378.23743	46.8275


Totals : 1.10284e5 1096.83508

*** End of Report ***

HPLC data of compound (\pm)-4f

Data File C:\CHEM32\1\DATA\NARESH\2015-07-20AB-KNB-2-250-R-OD-3-50-254-1-50M.D

Sample Name: AB-KNB-2-250-R-OD-3-50-254-1-50M




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.747	BB	0.2544	1.33140e4	767.55292	50.3227
2	9.554	BBA	0.6749	1.31432e4	293.25589	49.6773

Totals : 2.64572e4 1060.80881


*** End of Report ***

HPLC data of compound (R)-4f



Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-012-N11-OD-3-50-254-1-50M.D

Sample Name: AB-KNB-03-012-N11-OD-3-50-254-1-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.697	MM	0.6926	622.02673	14.96861	0.4542
2	9.218	BB	0.6744	1.36330e5	3068.00513	99.5458


Totals : 1.36952e5 3082.97373

*** End of Report ***

HPLC data of compound (R)-4f from (R)-4a



Data File C:\CHEM32\1\DATA\NARESH\2015-09-03AB-KNB-03-010-R-OD-3-50-254-1-50M.D
 Sample Name: AB-KNB-03-010-R-OD-3-50-254-1-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.676	VV	0.3572	2487.07837	98.29729	7.1947
2	9.114	MM	0.7370	3.20811e4	725.46271	92.8053

Totals : 3.45682e4 823.76000

*** End of Report ***

HPLC data of compound (±)-4g

Data File C:\CHEM32\...\NARESH\2018-01-1512-38-31AB-KNB-04-346-2-IE-3-40-1-254-40 M RACE.D
 Sample Name: AB-KNB-04-346-2-IE-3-40-1-254-40 M RACE




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.529	BV	0.3407	4.44467e4	1929.58862	49.5523
2	10.765	VB	0.5020	4.52498e4	1332.96252	50.4477


Totals : 8.96965e4 3262.55115

*** End of Report ***

HPLC data of compound (R)-4g



Data File C:\CHEM32\...A\NARESH\2018-01-1512-58-24AB-KNB-04-347-2-IE-3-40-1-254-40 M CHI.D
 Sample Name: AB-KNB-04-347-2-IE-3-40-1-254-40 M CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.602	MM	0.3599	4669.31934	216.20741	11.8231
2	10.810	BB	0.4874	3.48239e4	1059.78052	88.1769

Totals : 3.94932e4 1275.98793

*** End of Report ***

HPLC data of compound (\pm)-4h

Data File C:\CHEM32\...TA\NARESH\2018-03-1011-18-24AB-KNB-05-061-IB-30-1-254-50M-RACEMIC.D
 Sample Name: AB-KNB-05-061-IB-30-1-254-50M-RACEMIC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.715	BV	0.2161	3.65746e4	2451.00928	49.5987
2	6.652	VBA	0.3596	3.71663e4	1518.29858	50.4013


Totals : 7.37409e4 3969.30786

*** End of Report ***

HPLC data of compound (R)-4h




Data File C:\CHEM32\1\DATA\NARESH\2018-03-1011-32-49AB-KNB-05-061-IB-30-1-254-50M-CHIRAL.D
 Sample Name: AB-KNB-05-061-IB-30-1-254-50M-CHIRAL




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.727	MM	0.2430	3741.52417	256.66464	6.0244
2	6.658	BB	0.3800	5.83646e4	2254.83691	93.9756

Totals : 6.21061e4 2511.50156

HPLC data of compound (\pm)-4i

Data File C:\CHEM32\1\DATA\NARESH\2018-02-0619-14-30AB-KNB-E-02-205-IB-30-1-254-50M RAC.D
 Sample Name: AB-KNB-E-02-205-IB-30-1-254-50M RAC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.008	BB	0.3547	5.54719e4	2390.49780	49.7126
2	11.091	BBA	0.8487	5.61132e4	1012.32666	50.2874


Totals : 1.11585e5 3402.82446

*** End of Report ***

HPLC data of compound (R)-4i



Data File C:\CHEM32\1\DATA\NARESH\2018-02-0620-57-23AB-KNB-E-02-271-IB-30-1-254-50M CHI.D
 Sample Name: AB-KNB-E-02-271-IB-30-1-254-50M CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.064	BB	0.3577	8029.52490	339.73129	6.0901
2	10.915	MM	0.9542	1.23817e5	2162.68433	93.9099


Totals : 1.31846e5 2502.41562

*** End of Report ***

HPLC data of compound (\pm)-4j

Data File C:\CHEM32\1\DATA\NARESH\2018-03-1210-25-34AB-KNB-02-280-ID3-50-1-254-50M-RACE.D

Sample Name: AB-KNB-02-280-ID3-50-1-254-50M-RACE




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.375	BV	0.3940	1.75442e4	631.78333	49.4226
2	9.494	VBA	0.7071	1.79542e4	362.98605	50.5774

Totals : 3.54984e4 994.76938


*** End of Report ***

HPLC data of compound (R)-4j



Data File C:\CHEM32\1\DATA\NARESH\2018-03-1210-41-58AB-KNB-02-280-ID3-50-1-254-50M-CHI.D

Sample Name: AB-KNB-02-280-ID3-50-1-254-50M-CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.397	MM	0.5511	2061.82764	62.35340	1.7189
2	9.310	MM	0.7533	1.17887e5	2608.17261	98.2811


Totals : 1.19949e5 2670.52600

*** End of Report ***

HPLC data of compound (±)-4k

Data File C:\CHEM32\1\DATA\NARESH\2015-08-03AB-KNB-2-281-RACEMIC-3-OD-3-40-254-1-60.D

Sample Name: AB-KNB-2-281-RACEMIC-3-OD-3-40-254-1-60




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.985	BB	0.3610	1.78174e4	729.31091	50.1061
2	12.573	BBA	1.0449	1.77419e4	250.93648	49.8939

Totals : 3.55593e4 980.24739


=====
 *** End of Report ***

HPLC data of compound (R)-4k



Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-266-F-OD-3-40-254-1-60M.D

Sample Name: AB-KNB-03-266-F-OD-3-40-254-1-60M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.189	MM	1.5425	1613.61279	17.43466	2.9237
2	13.882	BBA	1.9180	5.35778e4	396.61786	97.0763


Totals : 5.51914e4 414.05252

=====
 *** End of Report ***

HPLC data of compound (\pm)-4l

Data File C:\CHEM32\1\DATA\NARESH\2015-08-03AB-KNB-2-279-RACEMIC-OD-3-40-254-1-60.D

Sample Name: AB-KNB-2-279-RACEMIC-OD-3-40-254-1-60




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.711	MM	0.3406	9148.41016	447.67456	49.2353
2	9.011	BB	0.8137	9432.57910	173.66725	50.7647


Totals : 1.85810e4 621.34181

*** End of Report ***

HPLC data of compound (R)-4I



Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-265-F1-OD-3-40-254-1-60M.D
 Sample Name: AB-KNB-03-265-F1-OD-3-40-254-1-60M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.659	MM	0.4098	1764.18835	71.75163	4.0898
2	9.132	MM	1.2439	4.13716e4	554.30914	95.9102

Totals : 4.31358e4 626.06078

*** End of Report ***

HPLC data of compound (\pm)-4m

Data File C:\CHEM32\...\NARESH\2018-01-2617-08-57AB-KNB-A-03-E-303-IB-40-1-254-50 M RACE.D
 Sample Name: AB-KNB-A-03-E-303-IB-40-1-254-50 M RACE




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.514	MM	0.2646	2.98346e4	1879.07813	50.6366
2	8.119	MM	0.5584	2.90844e4	868.13904	49.3634


Totals : 5.89189e4 2747.21716

*** End of Report ***

HPLC data of compound (R)-4m



Data File C:\CHEM32\...\NARESH\2018-01-2622-22-52AB-KNB-A-03-001-ADH-40-1-254-50M CHIRAL.D
 Sample Name: AB-KNB-A-03-001-ADH-40-1-254-50M CHIRAL




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.565	BB	0.2145	454.80374	31.11750	4.4828
2	8.176	BV	0.4949	9690.63867	281.99026	95.5172


Totals : 1.01454e4 313.10776

*** End of Report ***

HPLC data of compound (\pm)-4n

Data File C:\CHEM32\1\DATA\NARESH\2018-02-1317-34-13AB-KNB-05-048-ID3-50-1-254-50MRAC.D

Sample Name: AB-KNB-05-048-ID3-50-1-254-50MRAC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.043	VV	0.2780	4.92836e4	2457.59082	50.3397
2	6.270	MM	0.4505	4.86185e4	1798.77979	49.6603


Totals : 9.79021e4 4256.37061

*** End of Report ***

HPLC data of compound (R)-4n



Data File C:\CHEM32\1\DATA\NARESH\2018-02-1317-56-33AB-KNB-03-303-IB3-40-1-254-50MCHI.D
 Sample Name: AB-KNB-03-303-IB3-40-1-254-50MCHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.052	VB	0.2734	670.75250	33.53104	6.0841
2	6.260	BB	0.4213	1.03540e4	334.37375	93.9159

Totals : 1.10247e4 367.90479

*** End of Report ***

HPLC data of compound (\pm)-4o

Data File C:\CHEM32\1\DATA\NARESH\2018-02-1414-37-51AB-KNB-05-037R-ID3-30-1-254-50M RAC.D
 Sample Name: AB-KNB-05-037R-ID3-30-1-254-50M RAC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.959	VB	0.5579	3.32450e4	873.78833	49.9643
2	10.894	BB	0.8681	3.32924e4	559.60413	50.0357


Totals : 6.65374e4 1433.39246

*** End of Report ***

HPLC data of compound (R)-4o



Data File C:\CHEM32\1\DATA\NARESH\2018-02-1415-04-43AB-KNB-05-037R-ID3-30-1-254-50M CHI.D
 Sample Name: AB-KNB-05-037R-ID3-30-1-254-50M CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.099	MM	0.5332	4325.61035	135.20688	5.1425
2	10.796	MM	1.0725	7.97891e4	1239.91064	94.8575


Totals : 8.41147e4 1375.11752

*** End of Report ***

HPLC data of compound (\pm)-4p

Data File C:\CHEM32\1\DATA\NARESH\2018-02-1421-28-55AB-KNB-02-207-OD3-30-1-254-50M RAC.D

Sample Name: AB-KNB-02-207-OD3-30-1-254-50M RAC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.104	BV	0.1700	2.83956e4	2509.90649	49.7502
2	7.493	VB	0.2763	2.86807e4	1576.14160	50.2498


Totals : 5.70763e4 4086.04810

*** End of Report ***

HPLC data of compound (R)-4p



Data File C:\CHEM32\1\DATA\NARESH\2018-02-1421-16-00AB-KNB-02-207-OD3-30-1-254-50M CHI.D
 Sample Name: AB-KNB-02-207-OD3-30-1-254-50M CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.109	VB	0.1667	3396.52783	307.95407	6.8866
2	7.482	BBA	0.2746	4.59240e4	2543.94702	93.1134


Totals : 4.93205e4 2851.90109

*** End of Report ***

HPLC data of compound (\pm)-4q

Data File C:\CHEM32\1\DATA\NARESH\2016-06-15AB-KNB-03-292-AD-H-50-1-60M.D


Sample Name: AB-KNB-03-292-AD-H-50-1-60M




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.630	BB	2.1526	2533.41504	16.84519	50.0737
2	34.958	MM	2.9643	2525.95923	14.20229	49.9263

Totals : 5059.37427 31.04748

HPLC data of compound (R)-4q




Data File C:\CHEM32\1\DATA\NARESH\2016-06-16AB-KNB-03-310-F1-AD-H-50-1-60M.D
 Sample Name: AB-KNB-03-310-F1-AD-H-50-1-60M



Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	29.052	MM	3.3103	252.57382	1.27165	3.4654
2	35.361	MM	3.3765	7035.78955	34.72888	96.5346

Totals : 7288.36337 36.00053

HPLC data of compound (\pm)-4r

Data File C:\CHEM32\1\DATA\NARESH\2018-05-10AB-KNB-04-112-RAC-ID-3-40-254-50M.D

Sample Name: AB-KNB-04-112-RAC-ID-3-40-254-50M




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.212	MM	0.3040	3568.20166	195.62561	49.5866
2	10.420	BB	0.4554	3627.69629	119.09343	50.4134

Totals : 7195.89795 314.71904


*** End of Report ***

HPLC data of compound (R)-4r



Data File C:\CHEM32\1\DATA\NARESH\2018-05-10AB-KNB-05-123-4-CHI-ID-3-40-254-50M.D

Sample Name: AB-KNB-05-123-4-CHI-ID-3-40-254-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.189	MM	0.3595	94.03797	4.35985	0.8658
2	10.297	BB	0.4638	1.07675e4	345.30496	99.1342


Totals : 1.08615e4 349.66482

*** End of Report ***

HPLC data of compound (\pm)-4s

Data File C:\CHEM32\1\DATA\NARESH\2018-05-20AB-KNB-05-122-2-IC3-50-1-254-50M-RAC.D

Sample Name: AB-KNB-05-122-2-IC3-50-1-254-50M-RAC




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.862	BV	0.3542	4233.64746	178.82172	50.7486
2	6.469	VB	0.4538	4108.74316	138.63490	49.2514


Totals : 8342.39063 317.45662

=====
 *** End of Report ***

HPLC data of compound (R)-4s



Data File C:\CHEM32\1\DATA\NARESH\2018-05-20AB-KNB-05-127-2-IC3-50-1-254-50M-CHI.D
 Sample Name: AB-KNB-05-127-2-IC3-50-1-254-50M-CHI




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.934	MM	0.4297	1076.37744	41.74997	4.8484
2	6.448	MM	0.4175	2.11241e4	843.34790	95.1516


Totals : 2.22005e4 885.09787

*** End of Report ***

HPLC data of compound (±)-4t

Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-060-50-254-1-70M.D

Sample Name: AB-KNB-060-50-254-1-70M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.177	BB	0.2905	2.03153e4	1055.81726	50.2167
2	23.323	BB	1.0790	2.01400e4	285.49423	49.7833


Totals : 4.04553e4 1341.31149

*** End of Report ***

HPLC data of compound (*R*)-4t

Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-061-50-254-1-70M.D

Sample Name: AB-KNB-061-50-254-1-70M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.173	VB	0.2970	7107.71436	355.94263	24.7345
2	23.256	MM	1.1816	2.16283e4	305.07852	75.2655


Totals : 2.87360e4 661.02115

*** End of Report ***

HPLC data of compound (\pm)-8

Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-168-OD-3-50-254-1-40M.D

Sample Name: AB-KNB-03-168-OD-3-50-254-1-40M




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.423	MM	0.4080	4.33269e4	1769.70911	49.9355
2	12.898	BBA	1.0583	4.34388e4	601.63898	50.0645

Totals : 8.67657e4 2371.34808


*** End of Report ***

HPLC data of compound (R)-8



Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-231-OD-3-3-50-254-1-50M.D

Sample Name: AB-KNB-03-231-OD-3-3-50-254-1-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.705	MM	0.6229	582.06079	15.57285	0.4784
2	13.534	BB	1.2969	1.21085e5	1381.03748	99.5216


Totals : 1.21667e5 1396.61033

*** End of Report ***

HPLC data of compound (\pm)-9

Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-321-2-ADH-50-254-1;5-50M.D

Sample Name: AB-KNB-03-321-2-ADH-50-254-1;5-50M



Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.492	MM	0.3110	2.41114e4	1292.07007	50.9211
2	16.981	BB	0.8913	2.32392e4	389.91284	49.0789

Totals : 4.73506e4 1681.98291

=====


*** End of Report ***

HPLC data of compound (R)-9



Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-320-ADH-50-254-1;5-50M.D

Sample Name: AB-KNB-03-320-ADH-50-254-1;5-50M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.428	MM	0.2912	352.27847	20.16364	0.4899
2	16.796	BB	0.9376	7.15597e4	1138.11145	99.5101

Totals : 7.19119e4 1158.27509

=====
 *** End of Report ***

HPLC data of compound (\pm)-12

Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-323-RACEMIC-AD-3-30-254-1-40M.D
 Sample Name: AB-KNB-03-323-Racemic-AD-3-30-254-1-40M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.781	BB	0.7787	9.02859e4	1771.29431	49.5251
2	20.578	BB	0.9058	9.20173e4	1538.41589	50.4749


Totals : 1.82303e5 3309.71021

*** End of Report ***

HPLC data of compound (3*S*,3'*S*)-12

Data File C:\CHEM32\1\DATA\NARESH\AB-KNB-03-324-CHIRAL-R-AD-3-30-254-1-40M.D

Sample Name: AB-KNB-03-324-Chiral-R-AD-3-30-254-1-40M




Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.666	MM	0.8800	1.01056e5	1913.84778	99.6877
2	20.416	MM	0.7632	316.58658	6.91401	0.3123


Totals : 1.01372e5 1920.76179

*** End of Report ***

HPLC data of compound (\pm)-17

Data File C:\CHEM32\1\DATA\NARESH\2015-07-07 23-36-20AB-KNB-02-218-OZ-3-30-1-254-60.D

Sample Name: AB-KNB-02-218-OZ-3-30-1-254-60



Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.953	BB	0.2753	1677.64307	93.50455	37.6730
2	8.622	BB	0.6234	572.63696	14.23273	12.8591
3	10.671	BB	0.9090	548.16998	9.28238	12.3097
4	17.259	BB	1.8411	1654.72058	12.94718	37.1583

Totals : 4453.17059 129.96683

*** End of Report ***

HPLC data of compound (\pm)-17 under optimized condition

Data File C:\CHEM32\1\DATA\NARESH\2015-07-09 15-59-20AB-KNB-2-221-OZ-3-30-1-254-60.D
 Sample Name: AB-KNB-2-221-OZ-3-30-1-254-60




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.930	BB	0.2766	2.00435e4	1110.28333	21.9852
2	8.584	BV	0.6213	2.35663e4	583.36774	25.8492
3	10.538	VB	0.9167	2.35569e4	393.33795	25.8389
4	17.015	BB	1.8925	2.40015e4	193.31190	26.3266

Totals : 9.11682e4 2280.30092

*** End of Report ***

HPLC data of compound (\pm)-17

Data File C:\CHEM32\1\DATA\NARESH\2015-07-04 13-03-21AB-KNB-2-217-AS3-40-1--254-60.D
 Sample Name: AB-KNB-2-217-AS3-40-1--254-60




Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.241	MM	0.7369	5721.49902	129.40578	9.0956
2	7.115	MM	1.1251	2.57125e4	380.90805	40.8758
3	12.729	MM	1.9425	6027.63037	51.71767	9.5823
4	21.711	MM	3.3720	2.54422e4	125.75417	40.4462

Totals : 6.29038e4 687.78567

*** End of Report ***

HPLC data of compound (\pm)-19 under optimized condition

Data File C:\CHEM32\1\DATA\NARESH\2015-07-04 13-03-21AB-KNB-2-217-AS3-40-1--254-60.D
 Sample Name: AB-KNB-2-217-AS3-40-1--254-60



Signal 1: DAD1 A, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.241	BV	0.6631	5746.32031	129.13928	9.2159
2	7.115	VB	1.0013	2.57921e4	381.24588	41.3650
3	12.729	MM	1.8627	5680.24561	50.82446	9.1099
4	21.711	BBA	2.8471	2.51337e4	125.35922	40.3092

Totals : 6.23524e4 686.56884


*** End of Report ***

Cu-^tBu-PHOX preparation for EPR studies:


EPR experiment was performed with ^tBu-PHOX under nitrogen atmosphere. The EPR tube was evacuated and backfilled with argon and then CH₂Cl₂ was added to the mixture. The reaction mixture was irradiated under light for 1-2 min, and then an EPR spectrum was recorded and did not show any EPR signal.




The reaction was performed using 0.007 mmol of ^tBu-PHOX (**L4**) and 0.007 mmol of Cu(I)OTf·PhMe in an EPR tube under nitrogen atmosphere. The EPR tube was evacuated and backfilled with argon and then CH₂Cl₂ was added to the mixture. The reaction mixture was irradiated under light for 1-2 min and then an EPR spectrum was recorded and observed the EPR signal with a coupling constant ($g = 2.1120$) which indicates Cu(I) is converting to Cu(II) in the reaction course.




The reaction was performed using 0.034 mmol of ^tBu-PHOX (**L4**) and 0.034 mmol of Cu(OTf)₂ in an EPR tube under nitrogen atmosphere. The EPR tube was evacuated and backfilled with argon and then CH₂Cl₂ was added to the mixture. The reaction mixture was irradiated under light for 1-2 min and then an EPR spectrum was recorded and observed the EPR signal with a coupling constant ($g = 2.1062$) which indicates the Cu(II) complex is the intermediate in the reaction course.

EPR studies of Cu-complex with ^tBu-PHOX (L4)

X-band EPR spectra of ^tBu-PHOX (L4) at 110K under nitrogen atmosphere (solid sample).




X-band EPR spectra of a complex of 1 equiv. of Cu(I)OTf.PhMe with 1 equiv. of ^tBu-PHOX (L4) in dichloromethane at 110K under nitrogen atmosphere.




X-band EPR spectra of a complex of 1 equiv. of Cu(II)OTf with 1 equiv. of *t*Bu-PHOX (**L4**) in dichloromethane at 110K under nitrogen atmosphere.

Cu-*t*Bu-PHOX preparation for ¹H-NMR and ³¹P-NMR studies:

¹H-NMR of only *t*Bu-PHOX in CDCl₃ shows good splitting pattern of upfield protons.




The reaction was performed using 0.034 mmol of *t*Bu-PHOX (**L4**) and 0.034 mmol of Cu(OTf)₂ in an NMR tube under nitrogen atmosphere in CDCl₃. The NMR spectrum was recorded and observed no NMR signal of the free *t*Bu-PHOX protons in the spectrum. This indicates that Cu(II) complex (paramagnetic species) is forming.




The reaction was performed using 0.034 mmol of $^t\text{Bu-PHOX}$ (**L4**) and 0.034 mmol of $\text{Cu(I)OTf} \cdot \text{PhMe}$ in an NMR tube under nitrogen atmosphere in CDCl_3 . The NMR spectrum was recorded and observed the no NMR signal of the free $^t\text{Bu-PHOX}$ protons in the spectrum. This indicates that Cu(I) is converting to Cu(II) (paramagnetic species) complex.



^{31}P -NMR of only $^t\text{Bu-PHOX}$ in CDCl_3 shows ^{31}P signal at -5.96 ppm.




The reaction was performed using 0.034 mmol of $^t\text{Bu-PHOX}$ (**L4**) and 0.034 mmol of Cu(OTf)_2 in an NMR tube under nitrogen atmosphere in CDCl_3 . The ^{31}P NMR spectrum was recorded and observed no ^{31}P signal of the $^t\text{Bu-PHOX}$ in the spectrum. This indicates that phosphorus atom is bound with Cu(II) complex.




The reaction was performed using 0.034 mmol of $^t\text{Bu-PHOX}$ (**L4**) and 0.034 mmol of $\text{Cu(I)OTf} \cdot \text{PhMe}$ in an NMR tube under nitrogen atmosphere in CDCl_3 . The ^{31}P NMR spectrum was recorded and observed no ^{31}P -signal of the $^t\text{Bu-PHOX}$ in the spectrum. This indicates that phosphorus atom is bound with Cu(II) complex, which is converted from $\text{Cu(I)OTf} \cdot \text{PhMe}$.

^1H -NMR and ^{31}P -NMR studies of Cu-complex with $t\text{Bu}$ -PHOX (L4) **^1H -NMR of $t\text{Bu}$ -PHOX (L4) (400 MHz, 0.4 mL CDCl_3)**


^1H -NMR of $\text{Cu}(\text{OTf})_2 + {}^t\text{Bu-PHOX}$ (**L4**) (500 MHz, 0.4 mL CDCl_3), sample prepared under nitrogen atmosphere.




^1H -NMR of $(\text{CuOTf})_2 + {}^t\text{Bu-PHOX}$ (**L4**) (500 MHz, 0.4 mL CDCl_3), sample prepared under nitrogen atmosphere.



^{31}P -NMR of $t\text{Bu-PHOX}$ (**L4**) (400 MHz, 0.4 mL CDCl_3)



^{31}P -NMR of $\text{Cu}(\text{OTf})_2 + t\text{Bu-PHOX}$ (**L4**) (500 MHz, 0.4 mL CDCl_3), sample prepared under nitrogen atmosphere.




^{31}P -NMR of $(\text{CuOTf})_2 + {}^t\text{Bu-PHOX}$ (**L4**) (500 MHz, 0.4 mL CDCl_3), sample prepared under nitrogen atmosphere.

$\text{Cu-}^i\text{Bu-PHOX}$ (L2**) preparation for Cyclic Voltagram studies:**

Cyclic voltammetry (CV) were carried out by three electrode configuration with a glassy carbon (GC) working electrode, a platinum counter electrode, and standard calomel electrode (SCE) as reference electrode.

Reaction condition: $\text{Cu-}^i\text{Bu-PHOX}$ complex crystals (5 mg) in 5 mL CH_2Cl_2 containing 1.0 M tetrabutylammonium hexafluorophosphate (TBAPF_6).



Cyclic voltammogram of the complex in CH_2Cl_2 , potentials are vs SCE with Pt electrode using TBAP as supporting electrolyte.

Cyclic Voltammogram of $\text{Cu}(\text{OTf})_2 + i\text{Bu-PHOX}$ (**L2**)

X-ray structure of $\text{Cu}(\text{OTf})_2 + i\text{Bu-PHOX}$ complex:




Figure: X-ray structure of $\text{Cu}(\text{OTf})_2 + i\text{Bu-PHOX}$ with 50% thermal ellipsoids.

checkCIF/PLATON report

You have not supplied any structure factors. As a result the full set of tests cannot be run.

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: M2_a

Bond precision:	C-C = 0.0083 Å	Wavelength=0.71073
Cell:	a=9.3999 (9) b=22.436 (2) c=11.7542 (11)	
	alpha=90 beta=107.400 (2) gamma=90	
Temperature:	130 K	
	Calculated	Reported
Volume	2365.5 (4)	2365.4 (4)
Space group	P 21	P 21
Hall group	P 2yb	P 2yb
Moiety formula	C50 H52 Cu N2 O2 P2, C F3 O3 S	?
Sum formula	C51 H52 Cu F3 N2 O5 P2 S	C50 H51 Cu F5 N3 O3 P2 S
Mr	987.50	994.47
Dx, g cm ⁻³	1.386	1.396
Z	2	2
Mu (mm ⁻¹)	0.635	0.639
F000	1028.0	1032.0
F000'	1029.72	
h,k,lmax	12,29,15	12,29,15
Nref	11441 [5865]	11406
Tmin,Tmax	0.912,0.944	
Tmin'	0.909	

Correction method= Not given

Data completeness= 1.94/1.00 Theta(max)= 28.000

R(reflections)= 0.0491 (9001) wR2(reflections)= 0.1312 (11406)

S = 0.830 Npar= 590

The following ALERTS were generated. Each ALERT has the format

test-name_ALERT_alert-type_alert-level.

Click on the hyperlinks for more details of the test.

Alert level B

PLAT987_ALERT_1_B The Flack x is >> 0 - Do a BASF/TWIN Refinement Please Check

Alert level C

PLAT041_ALERT_1_C Calc. and Reported SumFormula Strings Differ Please Check
 PLAT043_ALERT_1_C Calculated and Reported Mol. Weight Differ by .. 6.97 Check
 PLAT068_ALERT_1_C Reported F000 Differs from Calcd (or Missing)... Please Check
 PLAT220_ALERT_2_C Non-Solvent Resd 1 C Ueq(max)/Ueq(min) Range 3.2 Ratio
 PLAT244_ALERT_4_C Low 'Solvent' Ueq as Compared to Neighbors of S004 Check
 PLAT341_ALERT_3_C Low Bond Precision on C-C Bonds 0.00831 Ang.

Alert level G

FORMU01_ALERT_2_G There is a discrepancy between the atom counts in the
 _chemical_formula_sum and the formula from the _atom_site* data.
 Atom count from _chemical_formula_sum: C50 H51 Cu1 F5 N3 O3 P2 S1
 Atom count from the _atom_site data: C51 H52 Cu1 F3 N2 O5 P2 S1
 CELLZ01_ALERT_1_G Difference between formula and atom_site contents detected.
 CELLZ01_ALERT_1_G ALERT: Large difference may be due to a
 symmetry error - see SYMMG tests
 From the CIF: _cell_formula_units_Z 2
 From the CIF: _chemical_formula_sum C50 H51 Cu F5 N3 O3 P2 S
 TEST: Compare cell contents of formula and atom_site data


atom	Z*formula	cif sites	diff
C	100.00	102.00	-2.00
H	102.00	104.00	-2.00
Cu	2.00	2.00	0.00
F	10.00	6.00	4.00
N	6.00	4.00	2.00
O	6.00	10.00	-4.00
P	4.00	4.00	0.00
S	2.00	2.00	0.00

PLAT033_ALERT_4_G Flack x Value Deviates > 3.0 * sigma from Zero . 0.032 Note
 PLAT244_ALERT_4_G Low 'Solvent' Ueq as Compared to Neighbors of C01Q Check
 PLAT398_ALERT_2_G Deviating C-O-C Angle from 120 Deg for O005 107.2 Degree
 PLAT398_ALERT_2_G Deviating C-O-C Angle from 120 Deg for O006 105.6 Degree
 PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels 110 Note
 PLAT791_ALERT_4_G The Model has Chirality at C00B (Chiral SPGR) S Verify
 PLAT791_ALERT_4_G The Model has Chirality at C00C (Chiral SPGR) S Verify

0 **ALERT level A** = Most likely a serious problem - resolve or explain
 1 **ALERT level B** = A potentially serious problem, consider carefully
 6 **ALERT level C** = Check. Ensure it is not caused by an omission or oversight
 10 **ALERT level G** = General information/check it is not something unexpected

6 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
 4 ALERT type 2 Indicator that the structure model may be wrong or deficient
 1 ALERT type 3 Indicator that the structure quality may be low
 6 ALERT type 4 Improvement, methodology, query or suggestion
 0 ALERT type 5 Informative message, check

Datablock: M2_a - ellipsoid plot



[Download CIF editor \(pubCIF\) from the IUCr](#)
[Download CIF editor \(enCIFer\) from the CCDC](#)
[Test a new CIF entry](#)